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Abstract
Pain in the postoperative period is a serious issue that can have a negative physical and
emotional impact on patient outcomes. Complications from postoperative pain can have
detrimental outcomes for patient’s health and wellbeing as well as the increased
economic burden of continued treatment. Better management of pain in the perioperative
phase can result in improved patient outcomes, fewer postoperative complications, and
increased patient satisfaction. Although opioids are the mainstay of treatment in the
perioperative period for pain management, abnormal pain responses such as hyperalgesia
may be induced by administration of opioids. The purpose of this systematic review is to
examine the effect of ketamine on reducing the phenomenon of opioid-induced
hyperalgesia. After a comprehensive literature search, the PRISMA Statement was used
to frame this systematic review and elevate the validity of the results by providing
transparency and clarity of the findings. The theoretical framework that guided this
systematic review was Melzack and Wall’s (1965) Gate Control Theory of Pain which
encompassed the physiologic and emotional responses of pain. Studies incorporated in
this systematic review were critically appraised to evaluate reliability of randomized
control trials. Variables such as intraoperative doses of opioids, intraoperative ketamine
doses, postoperative pain scores, postoperative opioid consumption, and evidence of
hyperalgesia were evaluated and put into tables for comparison. The results of this
systematic review support the use of ketamine in decreasing postoperative opioid
consumption, decreasing postoperative pain scores, and decreasing the incidence of
opioid induced hyperalgesia.
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EXAMINING THE EFFECTS OF KETAMINE ON REDUCING THE INCIDENCE OF
OPIOID-INDUCED HYPERALGESIA IN THE PERIOPERATIVE PHASE
Background/Statement of the Problem
The phenomenon of pain is a multifaceted problem that millions of Americans
endure. Pain involves not only a physical response to an injury that occurs, but an
emotional and psychological response as well. Failure to recognize all aspects of pain
and only focus on physical manifestations may lead to inadequate management of
symptoms. Approximately 40% of Americans struggle with chronic pain and pain is one
of the most common reasons for individuals to seek medical treatment in this country
(Flood, Rathmell, & Shafer, 2015). Bottemiller (2012) estimated that medical expenses
related directly to medical or surgical pain management along with indirect costs of lost
workdays and decreased productivity cost Americans approximately $635 billion per
year. These staggering statistics reveal the importance for health care providers to
understand the complexity of pain so that they may be better equipped to treat it.
Pain in the postoperative period is a serious issue that can have a negative impact
on patient outcomes. Poorly managed pain in the perioperative phase can result in
pathologic conditions such as deep vein thrombosis, pulmonary embolism, pneumonia,
and impaired wound healing (Apefelbaum, Chen, Mehta, & Gan, 2003). Pain can also
result in emotional and psychological complications such as demoralization, insomnia,
and patient dissatisfaction (Apefelbaum et al., 2003). These postoperative complications
can result in extended length of stay in the hospital, hospital readmissions, as well as the
economic burden of continued treatment (Apefelbaum et al., 2003). Better management
of pain in the perioperative phase can result in better patient outcomes, fewer
postoperative complications, and increased patient satisfaction.
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Opioids are a common class of drug that many health care providers utilize to
medically manage pain symptoms on a chronic outpatient basis, in the hospital setting, or
during the perioperative phase in surgical patients. There are many risks associated with
opioid use including physiological side effects, such as euphoria, respiratory depression,
constipation, miosis, bradycardia, and urinary retention (Flood et al., 2015). Some
untoward effects of opioids with chronic use include physical and psychological
dependence, tolerance, and hyperalgesia (Bottemiller, 2012). Opioid tolerance is defined
by Mauermann et al., (2015) as “desensitization to opioid effect requiring more opioid to
reach the same effect” (p. 460). Mauermann et al., (2015) also define opioid-induced
hyperalgesia as “an increase in pain sensitivity induced or aggravated by opioids” (p.
460). Since these two phenomena have a similar clinical presentation, it is imperative for
health care providers to differentiate between them because with tolerance, an increase in
opioid dosage will alleviate painful symptoms whereas with opioid-induced hyperalgesia,
an increased dose of opioids will intensify painful symptoms. The occurrence of
hyperalgesia after abrupt discontinuation of chronic opioids is well-documented;
however, recent research has indicated that high dose opioids for even a short period of
time, such as during the perioperative phase, can induce hyperalgesia (Bottemiller, 2012).
Treatment options for tolerance include increasing the dose of opioids and using a
multimodal approach to pain management to produce analgesia (Flood et al., 2015).
Treatment of opioid-induced hyperalgesia is still being researched, but many studies
point to N-methyl-D-aspartate (NDMA) antagonists such as ketamine as being a viable
option to manage this phenomenon (Bottemiller, 2012).

3
Reduction in postoperative complications, such as opioid-induced hyperalgesia
may result in improved patient outcomes and better patient satisfaction. The purpose of
this systematic review is to determine the possible effects that ketamine has on the
occurrence of opioid-induced hyperalgesia in adult surgical patients.
A review of the literature will be presented next.
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Literature Review
A literature search was conducted using the following key words: “pain”,
“hyperalgesia”, “opioid-induced hyperalgesia”, “ketamine”, “fentanyl”, “remifentanil”,
“sufentanil”, “prevention”, and “treatment”. The databases and websites used included
MEDLINE, PubMed, CINHAL, and Google Scholar. These sources provided relevant
research articles produced within the past 19 years for use within this review of the
literature.
Physiology of Pain
Pain is a complex phenomenon that is experienced, and described differently,
based on an individual’s perception of it. Pain is usually precipitated by a noxious
stimulus that creates an unpleasant sensation in the individual experiencing it. This
unpleasant sensation sometimes acts as a necessary protective mechanism to warn the
body against danger.
The human body is equipped with pain receptors called nociceptors located
throughout the entire body with the exception of the brain (Helms & Barone, 2008).
These nociceptors are free nerve endings that sense pain at the site of the harmful
stimulus and transmit information through an afferent pathway beginning in the dorsal
horn of the spinal cord and then traveling to the thalamus in the brain (Pandharipande &
McGrane, 2017). The limbic system and cerebral cortex also play a role in pain
interpretation and perception because pain is both an emotional and physical
phenomenon (Helms & Barone, 2008).
Pain involves the four phases of transduction, transmission, modulation, and
perception that make up the process of nociception, or the pain experience. Transduction
begins at the site of injury where the release of chemical mediators of pain respond to a
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noxious stimulus by converting the chemical information to sensory information (Flood
et al., 2015). Chemical mediators of pain such as histamine, substance P, bradykinin,
acetylcholine, leukotrienes, and prostaglandins are released by the damaged tissues
(Flood et al., 2015). These chemical mediators can cause a variety of physiological
reactions, such as inflammation at the site of the injury (Helms & Barone, 2008). Often it
is the inflammation itself that causes the sensation of pain and leads to the requirement of
analgesic medications to alleviate painful symptoms.
Transmission of chemical signals involves the pain signal moving from the
peripheral nervous system toward the central nervous system (Flood et al., 2015). There
are thought to be two types of nerve fibers that aid in pain transmission and sensation
along this afferent pathway: Aδ fibers and C fibers (Helms & Barone, 2008). Aδ fibers
are large fibers, myelinated fibers responsible for what Helms and Barone (2008)
describe as “first pain” or acute pain. The Aδ fibers facilitate a fast response to a stimulus
for the individual experiencing the pain. According to Helms and Barone (2008), the C
fibers are responsible for the “second pain” or the constant, prolonged, aching pain that
remains after the initial tissue injury.
Modulation of pain involves the release of inhibitory or excitatory
neurotransmitters that affect the way pain impulses reach the central nervous system.
Releasing certain inhibitory neurotransmitters such as endogenous opioids like
enkephalins, endorphins, serotonin, and norepinephrine can fully or partially block the
transmission of pain signals to the brain. These inhibitory neurotransmitters can also
prevent the release of some of the excitatory chemical mediators of pain such as
substance P, leading to decreased pain perception (Flood et al., 2015).
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Perceptions of Pain
Acute and Chronic Pain. Although there are many causes and descriptive
characteristics of pain, pain is usually separated into two categories; acute pain and
chronic pain. Acute pain is referred to as the initial pain that stimulates the sympathetic
nervous system’s fight or flight response. It usually decreases in severity over time and
provides a warning that an injury has occurred (Helms & Barone, 2008). Helms and
Barone (2008) describe chronic pain as sustained pain that lasts longer than what
constitutes as a normal healing time for an illness or injury. The concept of chronic pain
is poorly understood and difficult to manage (Helms & Barone, 2008). This can be due
to a variety of factors including the differences in how different populations experience
and describe pain.
Sex-based Differences in Pain Perception. Many differences exist in how pain
is described and reported based on patient demographics such as sex. Current literature
describes sex-based differences in pain reporting, in fact Helms and Barone (2008) note
that women report pain more frequently than men and with greater intensity. For
instance, chronic pain disorders such as fibromyalgia and migraines are found to be more
prevalent in female populations than men (Helms & Barone, 2008; Paller, Campbell,
Edwards, & Dobs, 2009). This could be due in part to recent research suggesting that
brain activity in men and women vary during painful experiences (Paller et al., 2009). In
their review on sex-based differences in pain perception and treatment, Paller et al.,
(2009) described differences seen between men and women on magnetic resonance
imaging (MRI). In patients diagnosed with irritable bowel syndrome (IBS) experiencing
mild rectal distension, MRI studies showed that this pain activated the left thalamus and
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ventral striatum of the brain in men, whereas in women, this painful stimulus deactivated
areas of the amygdala and mid-cingulate (Paller et al., 2009). Men experienced greater
activation of the insula compared to females during anticipation of pain (Paller et al.,
2009).
Background. The limbic system in the brain is involved with the behavioral and
emotional response to pain and contains the hypothalamus, insula, ventral striatum,
amygdala, and hippocampus (Hall, 2016). The ventral striatum in the basal ganglia of the
brain contains the nucleus accumbens which is involved in dopamine secretion and
reward pathways (Hall, 2016). This area of the brain has been shown to be activated
during anticipation of or experience of pleasant events, but the significance of activation
during painful events in men is poorly understood (Paller et al., 2009). Jensen et al.,
(2003) hypothesized that activation of the ventral striatum during painful experiences
may be due to anticipation of pain cessation. The amygdala is a part of the limbic system
involved learning and subconscious behavior awareness that allows humans to
appropriately express anxiety and fear (Hall, 2016). The mid-cigulate is a component of
the paralimbic region and receives inputs from the amygdala (Jensen et al., 2003). Paller
et al., (2009) inferred that deactivation of these areas in the brain as seen on MRI in the
female population may be due to greater familiarity with pelvic pain in women. The
insula is part of the limbic system involved in relaying sensory information regarding
reactions to pain and processing emotions (Jensen et al., 2003). Sex-based differences in
activation and deactivation of these areas of the brain may contribute to differences in the
processing of actual or anticipated painful stimuli in men and women (Paller et al., 2009).
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Age Related Differences in Pain Perception. Helms and Barone (2008) also
compared pain perception in children to pain perception in the elderly. These researchers
note that it is often a misconception that infants and children do not experience pain due
to their immature nervous systems. On the contrary, pain can be experienced by fetuses
as young as 24 weeks gestation because their central nervous system is usually formed
and functioning by that time (Mathew & Mathew, 2003; Helms & Barone, 2008).
Nociceptive impulses in infants travel to the spinal cord through unmyelinated fibers
rather than the myelinated fibers utilized by adults for pain transmission (Mathew &
Mathew, 2003). Infants also have higher concentrations of substance P than adults
(Mathew & Mathew, 2003). This suggests that infants may experience more pain than
adults due to their lower nociceptive threshold.
Pain experienced by infants and children during the developing years may have
long-term behavioral and psychological consequences and may also increase perceptions
of pain as children grow older (Helms & Barone, 2008). Negative long term effects of
pain in neonates have been demonstrated in many studies and include Alzheimer’s
disease, depression, anxiety, and hyperalgesia (Correa et al., 2018). These potential
detrimental effects are related to damage to the peripheral and central pain pathways
during neurodevelopment. In their prospective interventional case control study,
Gajbhiye, Rao, and Singh (2018) aimed to compare the analgesic effects of breast feeding
and oral sucrose in full term, healthy, breastfed, vaginally delivered newborns. Their
study included 150 newborns who were separated into three groups: group I, n=50
(control), group II (interventional), n=50, and group III (interventional), n=50. There
were 74 male and 76 female newborns included in this study. These newborns were
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observed during administration of a painful, intramuscular hepatitis B vaccine.
Newborns in group I were treated as the control group and received their vaccination
without intervention while sitting on their mother’s lap. Newborns in group II were
given 1 ml of 25% oral sucrose two minutes prior to administration of the vaccine and
were also held on their mother’s lap during vaccination. Newborns in group III were
breastfed two minutes prior to vaccination and were also given the vaccine while on their
mother’s lap. The neonate’s pain was evaluated using a Premature Infant Pain Profile
(PIPP) scale which has been accepted to be a reliable and valid tool used to quantify pain
in infants (Duhn & Medves, 2004). PIPP examines variables such as gestational age,
behavioral state, heart rate, oxygen saturation, brow bulge, eye squeeze, and nasolabial
furrow to measure pain in infants. Cry time was also measured and calculated for 30, 60,
90, and 120 seconds after vaccination. PIPP scores were considered the primary outcome
of this study. The mean PIPP scores were significantly lower (p < 0.0001) in infants in
group III who were breast fed, compared to those group II who were given oral sucrose
or group I who was given no intervention. The duration of cry time was lower in group
III compared to groups I and II; however, the results were not significant (p > 0.05). The
results of this research suggest that infants not only experience pain, but that breast
feeding provides superior analgesia to oral sucrose in decreasing pain with intramuscular
injection of a vaccine (Gajbhiye, Rao, & Singh, 2018).
The elderly population is also not well understood when it comes to pain
management. In their 2008 review of the physiology of pain, Karp, Shega, Marone, and
Weiner (2008) note that elderly individuals rely more on C fibers, or delayed, “second
pain” sensations, rather than Aδ fibers, or fast “first pain” sensations, which younger
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adults utilize for pain transmission. This delayed response to pain causes older adults to
have a slower response to painful stimuli and is thought to be related to physiologic
changes associated with aging in the density of myelinated Aδ fibers (Karp et al., 2008).
A seminal study by Chakour, Gibson, Bradbeer, and Helme (1996) studied this
phenomenon in their randomized control trial where they explored age related changes in
pain perception in 30 healthy adults. Fifteen young adults between 20-40 years old
(mean age: 26.1 years) and fifteen elderly adults over the age of 65 (mean age: 74.1
years) participated in this study. Researchers measured thermal thresholds of pain,
mechanical thresholds of pain, and reaction times before, during, and after a radial
compression block was performed. Pain was inflicted using a CO2 laser to provoke a
thermal stimulus in the subjects. Chakour et al., (1996) performed a radial compression
block using two 1.3 kg weights that were suspended in order to impair myelinated Aδ
fibers while keeping C fiber function intact. Their procedure examined three different
testing periods: pre-block, block, and post-block where they measured temperature
threshold, mechanical sensory threshold, thermal pain threshold, and reaction times.
Efficacy of the block was proven through testing temperature thresholds. The results
showed that regardless of age, all subjects lost cold sensation and retained warm
sensation after the block, although there was a trend in the elderly group that suggested
they had an increased thermal threshold. Chakour et al., (1996) found a significant
difference in the elderly group’s description of pain where they used words such as “hot,
burning, or stinging” (p. 148) which are commonly associated with C fiber activation
during all three testing periods. They found that prior to the block and after the
compression block the young group used words such as “sharp and pricking” (p. 148)
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which are associated with Aδ fiber activation and during the compression block, they
used words associated with C fiber activation. Reaction times were measured by asking
participants to press a button with their dominant hand when they felt the stimulus from
the CO2 laser. Pre and post-block, the mean results of reaction times for the young group
was <600 milliseconds (ms) and during the block the mean results were 1,600 ms. The
older adults had a mean reaction time of 1,100 ms pre and post-block and a mean reaction
time of 2,100 ms during the block (Chakour et al., 1996). The results supported the
hypothesis that young adults rely heavily on Aδ fibers for pain transmission and had
quicker response times compared to the elderly patients who were found to rely more on
C fibers for pain transmission and had slower response times (Chakour et al., 1996).
Although pain transmission may be delayed in older adults, pain intensity does
not decrease with age as is often believed. This was described by Helms and Barone
(2008) as altered and atypical reactions and descriptions of pain from the elderly
population. These atypical reactions and descriptions of pain can manifest as delirium
due to diminished cognitive abilities related to aging. Gagliese and Melzack (2003)
performed a randomized control trial to examine differences in pain intensity and quality
in elderly chronic pain patients compared with young chronic pain patients. These
researchers evaluated 565 randomly selected participants over a 5-year period.
Participants were assigned to two groups based on age with one group younger than 60
years old and one group older than 60 years old. In order to reduce confounding
variables, participants from each group were equally matched regarding diagnoses, pain
location, sex, and duration of pain, resulting in a total of 278 individuals participating in
this study (Gagliese & Melzack, 2003). Data was measured in the younger group
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(n=139; mean age = 42.93) and elderly group (n=139; mean age = 70.12) utilizing the
McGill Pain Questionnaire (MPG) which is a widely used, valid, and reliable tool
consisting of 20 adjectives to describe different components of pain (Gagliese &
Melzack, 2003). Patients were also asked to rate their highest pain using the Numerical
Rating Scale (NRS-H), usual pain (NRS-U), and lowest pain (NRS-L) levels over the
past week on a Numerical Rating Scale (NRS). A Pain management index (PMI) was
also created for each patient to compare the potency of analgesic medication these
patients receive with their highest pain scores to examine if these patients receive
adequate analgesia (Gagliese & Melzack, 2003). Elderly patients were found to have
lower sensory scores and used fewer descriptors of pain using the MPQ in comparison to
the young patients. There were, however, no significant differences in pain scores when
using the NRS (Gagliese & Melzack, 2003). These results suggest that although pain
quality may decrease with age, pain intensity remains the same (Gagliese & Melzack,
2003).
Opioid Receptors
Opioid receptors are a group of G-coupled protein receptors that exist within the
central nervous system at presynaptic and postsynaptic sites. These sites are located in
the amygdala, corpus striatum, and hypothalamus of the brain, periaqueductal gray
matter, rostral ventral medulla (RVM), locus ceruleus in the brainstem, and the substantia
gelatinosa in the dorsal horn of the spinal cord, and in the periphery (Flood et al., 2015).
G-coupled proteins are intracellular proteins that are involved in transmission of signals.
When G-proteins are bound to guanine diphosphate (GDP) they are inactivated, or “off”,
and when G-proteins are bound to guanine triphosphate, they are activated, or “on”
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(Flood et al., 2015). Agonism of the opioid receptor by endogenous or exogenous
opioids causes a conformational change and activation of the G-coupled protein receptor.
This causes the GDP to be exchanged for GTP resulting in inhibition of adenylyl cyclase
and a reduction of intracellular cyclic adenosine monophosphate (cAMP) (Pathan &
Williams, 2012). Decreased cAMP within the cell results in hyperpolarization of the cell,
activation of intracellular potassium channels, and inhibition of intracellular calcium
channels, resulting in reduction in release of excitatory neurotransmitters and therefore,
reduced pain perception (Pathan & Williams, 2012).
There are four major opioid receptors that aid in decreasing nociception: mu1,
mu2, kappa, and delta. Mu1, kappa, and delta receptor activation are involved in
producing supraspinal analgesia, while mu2 receptor activation produces spinal analgesia.
Consequences of activating Mu1 receptors may cause euphoria and miosis while
activation of Mu2 receptors may induce respiratory depression (Flood, et al., 2015).
Activation of kappa receptors produce dysphoria, sedation, and miosis and activation of
delta receptors may cause urinary retention, constipation, and respiratory depression
(Flood, et al., 2015). Mu1 and kappa activation through analgesics provide low abuse
potential for those medications while Mu2 and delta activation may be responsible for the
high abuse potential in certain opioids (Flood, et al., 2015).
Endogenous opioids such as enkephalins, endorphins, and dynorphins as well as
exogenous opioid medications can act as ligands and activate these opioid receptors
resulting in decreased transmission of pain signals. As endogenous or exogenous
opioids bind to these receptors, calcium influx is prevented, and hyperpolarization of
potassium channels occurs. This inhibits the release of chemical mediators of pain, such
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as substance P, which has been implicated in inducing a painful response (Flood et al.,
2015).
Opioid receptors are also involved in regulating signals in N-methyl-D-aspartate
(NMDA) receptors, which are found in nerve cells (Jamero, Borghol, Vo, & Hawawini,
2011). The NMDA receptor acts as the receptor for the neurotransmitter, glutamate,
which is also released when individuals are exposed to painful stimuli. The activation of
NMDA receptors causes increased sensitivity to pain and perception of pain while also
decreasing the effectiveness of opioid receptors (Jamero et al., 2011).
Treatment of Pain: Opioid Analgesia
Opioid receptors exist throughout the body in order to dampen pain signals
through their activation by endogenous or exogenous opioids. Once a painful stimulus
has warned the body against danger, there is no reason for the individual to remain in
pain because the pain is no longer serving a useful purpose (Flood et al., 2015). There
are many pharmacological and nonpharmacological therapies to remedy painful
symptoms, depending on the type of pain the patient is experiencing. Regardless of the
method, the goal of treatment is to alleviate pain or at least make it tolerable for the
patient to achieve and maintain a comfortable quality of life.
Classification of Opioids. Opioids can be classified as naturally occurring
compounds, semi-synthetic compounds, or synthetic compounds and classified as an
opioid agonist, agonist-antagonist, or antagonist based on their effect at the opioid
receptor (Pathan & Williams, 2012). Naturally occurring opioid agonists include opioids
such as morphine and codeine. Semi-synthetic opioid agonists include oxycodone,
heroin, dihydromorphone, and buprenorphine while synthetic opioid agonists include
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medications like methadone, fentanyl, and analogues of fentanyl such as remifentanil,
alfentanil, and sufentanil. The synthetic compounds can be further separated into four
different groups: morphanian derivatives, diphenylheptane derivatives, benzomorphan
derivatives, and phenylpiperidine derivatives, which include fentanyl and its analogues
(Pathan & Williams, 2012). Whether endogenous, naturally occurring, semi-synthetic, or
synthetic, most opioid agonists exert the majority of their effects on the mu receptors
with some having effects on kappa and delta receptors as well (Flood et al., 2015).
Morphine. Morphine is a naturally occurring opioid agonist that is recognized as
the prototype opioid agonist which all other opioids are derived from and compared to
(Flood et al., 2015). It is thought that as early as 3000 B.C. the active extract P.
somniferum from the opium poppy was being utilized for analgesic properties (Pathan &
Williams, 2012). Morphine was first isolated as the active compound in the opium poppy
in 1806 by a German pharmacist and soon after was chemically manipulated to develop
semi-synthetic and synthetic opioid agonists (Pathan & Williams, 2012). Morphine
exerts its effects predominantly on the mu receptors producing analgesia, even at low
doses, as well as euphoria, sedation, respiratory depression, dry mouth, and pruritis
(Flood, 2015).
Morphine can be administered intravenously (IV), intramuscularly (IM), or by
mouth (PO) but is usually administered IV in the perioperative period. The onset of
morphine after IV administration is delayed compared to that of synthetic opioids such as
fentanyl and its analogues. The peak effects of IV morphine occur in 15 to 30 minutes
after administration and duration can last 1-4 hours, whereas the peak effects of fentanyl
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occur within 2-3 minutes and the duration is much shorter lasting only 30-45 minutes
(Pathan & Williams, 2012).
Fentanyl. According to Casserly and Alexander (2017), fentanyl is one of the
most prevalently used opioids intraoperatively. Fentanyl is a synthetic derivative of the
opioid morphine but is about 100 times more potent than morphine (Casserly &
Alexander, 2017). Its highly lipophilic nature allows the drug to be rapidly distributed to
highly perfused tissues and organs within the body and more slowly distributed to muscle
and fat (Casserly & Alexander, 2017; Pandharipande & McGrane, 2017). The onset of
action of fentanyl is about 3 to 5 minutes, but it can have a longer half-life depending on
whether it is administered as a bolus dose or as an infusion during or after a procedure
(Casserly & Alexander, 2017). Due to its context-sensitive half-life, infusions are not
preferred for use in short surgical cases due to its potential for inducing lengthy sedation
(Casserly & Alexander, 2017).
Sufentanil. Sufentanil is an analogue of fentanyl that is about 10 times more
potent than fentanyl and 1000 times more potent than morphine (Flood et al., 2015). Its
onset after IV administration is almost immediate with peak effects occurring in less than
5 minutes and duration lasting about 30 minutes (Nagelhout & Plaus, 2014). Sufentanil
is used intraoperatively for a variety of surgical procedures and has been shown to
prolong analgesia and induce less respiratory depression compared with both fentanyl
and morphine resulting in earlier emergence from anesthesia and earlier extubation
(Flood et al., 2015).
Remifentanil. Remifentanil is a derivative of fentanyl that is also frequently used
for opioid analgesia intraoperatively. It is about one to two times stronger than fentanyl
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but is similar in the sense that it is also highly lipophilic and can be rapidly distributed to
tissues and organs (Casserly & Alexander, 2017). Some of the advantages of
remifentanil compared to fentanyl are its shorter onset of action of 1 to 2 minutes and its
shorter half-life and context-sensitive half time, regardless of whether it is administered
as a bolus or an infusion, making it the preferred opioid for short surgical procedures
(Casserly & Alexander, 2017; Pandharipande & McGrane, 2017).
Opioids in the Perioperative Phase
In patients undergoing surgical procedures, pharmacological pain management is
standard practice. Patients in the perioperative phase, a term encompassing the
preoperative, intraoperative, and postoperative phases, typically receive opioid analgesia
throughout their surgical experience (Pandharipande & McGrane, 2017). In addition to
pain control, opioids provide benefits during induction of anesthesia to attenuate the
hemodynamic response to direct laryngoscopy and endotracheal intubation
(Gurulingappa, Aleem, Awati, & Adarsh, 2012). During direct laryngoscopy and
endotracheal intubation, patients experience a reflexive tachycardia and hypertension that
may be detrimental to patients with preexisting cardiac disease (Gurulingappa et al.,
2012). Opioids have been shown to attenuate the sympathetic response to direct
laryngoscopy and endotracheal intubation by increasing parasympathetic tone and
blunting airway reflexes during induction of anesthesia (Gurulingappa et al., 2012;
Pathan & Williams, 2012). In their randomized control trial, Gurulingappa et al., (2012)
compared the effects of fentanyl, lidocaine, and a placebo of normal saline on the
cardiovascular response to direct laryngoscopy and endotracheal intubation. Their
subjects included 75 male and female, ASA I patients, between the ages of 20 and 60
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years old, undergoing a routine elective surgical procedure. Group one received 4
mcg/kg of fentanyl, group two received 1.5 mg/kg of lidocaine, and group three received
a placebo of normal saline during induction of anesthesia to examine which drug would
provide the greatest hemodynamic stability during direct laryngoscopy and endotracheal
intubation. Gurulingappa et al., (2012) concluded that the incidence of tachycardia and
hypertension in the lidocaine and placebo groups were significantly greater (p < 0.05)
than that of the fentanyl group. Although lidocaine also provided some attenuation of the
reflexive tachycardia and hypertension observed with direct laryngoscopy and
endotracheal intubation, fentanyl offered a more reliable hemodynamic stability during
induction of anesthesia (Gurulingappa et al., 2012).
Although opioids have benefits during the perioperative phase such as providing
analgesia and maintaining hemodynamic stability direct laryngoscopy, endotracheal
intubation, and surgical manipulation of the patient, opioids may be associated with
adverse effects such as decreased level of consciousness, respiratory depression,
muscular rigidity, pruritis, nausea, vomiting, urinary retention, and hyperalgesia (Pathan
& Williams, 2012). Different pharmacodynamic properties of natural, semi-synthetic,
and synthetic opioids produce a variety of effects. Flacke et al., (1985) performed a
double-blind randomized control trial comparing the use of morphine, meperidine,
fentanyl, and sufentanil in 60 healthy adult patients undergoing general anesthesia for
elective procedures. Patients were split into four groups and equipotent doses of these
four opioids were administered to these patients during the perioperative phase.
Variables such as histamine release, catecholamine concentrations, hemodynamic data
including incidence of tachycardia, and respiratory depression were examined.
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Researchers found that use of narcotics such as morphine and meperidine correlated with
significant increases in catecholamine levels, histamine release, and incidence of
tachycardia when compared with the groups that received fentanyl and sufentanil.
Respiratory depression was markedly increased in the postoperative phase in patients
who received morphine and occurred least in the group that received sufentanil (Flacke et
al., 1985).
Fleischman et al., (2010) performed a retrospective study examining the efficacy
of a protocol change from morphine to fentanyl for out-of-hospital analgesia for
emergency medical services (EMS) in Multnomah County, Oregon. A total of 718
patients, ages 13-99 years old were chosen for this research study. Researchers aimed to
compare the differences in pain scores on a numerical rating scale (NRS) of 0-10, as well
as to compare and assess the incidence of adverse side effects of morphine and fentanyl.
Some parameters examined included respiratory rate less than 12 breaths per minute,
pulse oximetry less than 92%, requirement of intubation, systolic blood pressure less than
90 mm Hg, nausea or vomiting, decrease in Glasgow Coma Scale score, and
requirements of naloxone administration (Fleischman et al., 2010). Three hundred fiftyfive patients in the study received morphine prior to the protocol change and 363 received
fentanyl after the protocol change. There was no significant difference in pain scores
when equivalent doses of fentanyl and morphine were given (Fleischman et al., 2010).
There was a low rate of negative effects (0.8% to 7.3%) resulting from either fentanyl or
morphine administration. The most common adverse effect experienced by patients in
this study was nausea which occurred 7% of the time in patients receiving morphine
compared to 3.8% incidence of nausea when fentanyl was administered. Other adverse
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effects measured that were previously mentioned occurred 0.5% to 2.3% of the time in
both groups (Fleischman et al., 2010). Fleischeman et al., (2010) concluded that both
fentanyl and morphine were efficacious at treating pain with a low rate of adverse events
and statistically significant differences were not observed in their study.
Quantifying Pain for Best Treatment
Pain can be quantified using different scales and methods depending on whether
the target population is able to verbalize and describe their pain. Capabilities of selfreporting pain can be multifactorial, depending on variables such as age, developmental
capability, and condition of the patient. Determinants of the appropriate pain scale that
health providers may use to quantify pain is dependent on the age of the patient and
whether the patient is able to self-report pain.
Williamson and Hoggart (2005) performed a review of three scales that are
commonly used to quantify pain in patients who are capable of self-reporting pain in
order to examine the reliability and validity of these scales. The scales included in the
review are the visual analogue scale (VAS), numerical rating scale (NRS), and verbal
rating scale (VRS) (Williamson & Hoggart, 2005). The VAS can be used in cognitively
intact individuals to visually describe their pain on a 10 cm linear scale with 100 mm
markings, with different descriptors of pain along the scale ranging from ‘no pain’ to
‘worst pain imaginable’ (Williamson & Hoggart, 2005). The score is determined after
the patient marks where their pain lines on the scale, with a higher score being indicative
of more pain (Williamson & Hoggart, 2005). The pain scale that is most commonly used
in clinical practice for individuals capable of describing their pain is the NRS, which
quantifies pain on an 11 point scale where pain is given a rating of 0 to 10. A score of 0
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is indicative of no pain and 10 describes the worst pain imaginable (Williamson &
Hoggart, 2005; Helms & Barone, 2008). The VRS is a pain scale also used by
individuals capable self-reporting pain. The VRS involves rating pain on a scale of zero
to three to describe the level of pain. This four-point scale quantifies the intensity of pain
by assigning the adjectives to describe pain levels: 0 = no pain, 1 = mild pain, 2 =
moderate pain, and 3 = severe pain (Williamson & Hoggart, 2005). Lara-Munoz, Deleon,
Feinstein, and Wells (2004) performed a study aimed at examining the efficacy of the
VAS, VRS, and NRS. They conducted this prospective, clinometric study with 30
individuals using sound to produce painful stimuli. Tones of 1000 Hz with different
intensities were administered and pain levels were recorded on the VAS, VRS, and NRS
to explore if the results correlated among these three different scales (Lara-Munoz et al.,
2004). The results of the study indicate that all three pain scales are reliable and valid,
however; the VRS was shown to be the least sensitive of these tools and the VAS and
NRS displayed equal sensitivity (Lara-Munoz et al., 2004). The NRS was shown to be
easiest to use tool while the VAS was the most difficult to use tool (Lara-Munoz et al.,
2004).
Individuals who cannot self-report pain due to cognitive impairment, sedation,
anesthesia, or critical physiologic condition prove to be difficult to assess for pain. There
are different scales available such as the Behavioral Pain Scale (BPS) and the Critical
Care Observation Tool (CPOT) which use indicators such as facial expression, limb
movement, and ventilator compliance to assess and treat assumed pain in these
populations (Kampo et al., 2013; Pandharipande & McGrane, 2017). The CPOT is
frequently used in critically ill individuals who are incapable of self-reporting pain. It
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allows critically ill patient’s pain to be quantified by assessing four components,
including facial expression, body movements, ventilator compliance, and muscle tension
that may be observable to healthcare professionals and indicate pain in this population
(Khanna, Pandey, Chandralekha, Sharma, & Pangasa, 2018). This tool can also be
modified for use in critically ill, spontaneous breathing patients by substituting the
category of ventilator compliance with vocalization (Khanna et al., 2018). Khanna et al.,
(2018) performed a prospective observational study to examine the efficacy of the CPOT
in 180 critically ill, mechanically ventilated, sedated adults in the intensive care unit
(ICU) by comparing the CPOT scores to hemodynamic changes in arterial blood pressure
and heart rate during painful procedures. Researchers obtained baseline CPOT scores
and vital signs while patients were at rest and then three times per day during
endotracheal suctioning and patient repositioning, which were assumed to be painful
procedures. Khanna et al., (2018) found that during these painful procedures, there was a
significant (p <0.001) increase in baseline systolic and diastolic blood pressures, but no
significant rise in heart rate. These cardiovascular changes correlated with CPOT scores,
indicating that the CPOT was an accurate and reliable tool that may be used in patients
who are unable to self-report pain (Khanna et al., 2018).
When patients are under general anesthesia in the operating room, anesthesia
providers may struggle to identify and quantify pain during the surgical procedure.
Patients under general anesthesia may display a variety of physiologic responses to pain
such as increased blood pressure, increased heart rate, and increased respiratory rate
(Kampo et al., 2013). Despite recognizing these hemodynamic changes, it may be
difficult for the anesthesia provider to distinguish between inadequate depth of anesthesia
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and pain during the intraoperative period. In order to assist anesthesia providers in
making this distinction, Kampo et al., (2013) created the Anesthetized Patient Pain Scale
(APPS) and examined its efficacy by using a cerebral state monitor (CSM) to also assess
depth of anesthesia in their prospective study. The APPS is a pain assessment tool that
quantifies pain in anesthetized patients by accounting for hemodynamic, physiologic, and
behavioral changes that may occur intraoperatively (Kampo et al., 2013). The APPS
measures cardiovascular responses to pain such as blood pressure, heart rate, and
respiratory rate along with behavior responses to pain such as facial expression, muscle
tension, and body movement. In order to quantify pain, a score from 1-3 is given to each
category. A minimum possible score of 6 indicates no pain, scores of 7-8 indicate
moderate pain, scores of 9-12 indicate moderate-severe pain, and a maximum possible
score of 18 indicates severe pain (Kampo et al., 2013). The CSM is a device that utilizes
electroencephalogram (EEG) waves to monitor depth of anesthesia (Kampo et al., 2013).
CSM readings of 0-10 indicate a comatose state, 10-40 indicate deep anesthesia, 40-60
indicate adequate depth of anesthesia, 60-80 indicate light anesthesia, and 90-100
indicate an awake patient (Kampo et al., 2013). Kampo et al., (2013) included 250,
healthy orthopedic patients with no known comorbidities to participate in their
prospective study. All of these subjects underwent general anesthesia for their surgical
procedure. Their findings indicated that out of the 250 participants, 150 of those had
adequate depth of anesthesia as demonstrated by CSM scores; however, 68.7% of those
patients APPS scores still indicated moderate to severe pain. Researchers treated
intraoperative pain with 30-50 mcg fentanyl and then re-evaluated pain scores using the
APPS. Their results showed a statistically significant (p <0.001) difference in intensity
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of pain after fentanyl administration while using the APPS and CSM intraoperatively.
This indicates that the APPS may be an effective tool for assessing intraoperative pain
while used in conjunction with the CSM to help minimize complications postoperative
pain (Kampo et al., 2013).
Abnormal Pain Perception
Disorders of pain perception such as hyperalgesia and allodynia can occur when
the C fibers, which are responsible for the second or prolonged pain, are overstimulated
(Flood et al., 2015). Hyperalgesia is defined by Helms and Barone (2008) as “a
heightened pain response to a stimulus that is painful” (p. 43). Primary hyperalgesia is
defined by Flood et al., (2015) as hyperalgesia that occurs at “the original site of injury”
(p. 205) and secondary hyperalgesia as the pain that occurs “in the uninjured skin
surrounding the injury” (p. 205). Allodynia is defined by Helms and Barone (2008) as
“pain from a stimulus that does not normally produce pain, such as touch” (p.43). These
two disorders of intensified pain perception are attributed to the central sensitization
phenomenon (Helms & Barone, 2008; Flood et al., 2015).
Central sensitization of the nociceptors occurs due to overstimulation of the C
nerve fibers which damages these nerve fibers resulting in an increased sensitivity to
painful stimuli (Flood et al., 2015). Conditions such as chronic pain are associated with
prolonged release of inflammatory mediators which overstimulates C fibers, leading to
disordered pain perception. With an acute painful process, once the inflammatory
process resolves, the nerve fibers are able to return to their original state with a normal
threshold for painful stimuli (Flood et al., 2015).
Opioid-Induced Hyperalgesia Versus Tolerance
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Background. Opioids, such as fentanyl and its analogues sufentanil and
remifentanil, have been believed to induce hyperalgesia, which has long been confused
with acute and chronic tolerance to these medications (Lee & Yeomans, 2014).
Tolerance to opioids is defined by Mauermann et al., (2015) as “desensitization to opioid
effect requiring more opioid to reach the same effect” (p. 460). These authors further
define opioid-induced hyperalgesia as “an increase in pain sensitivity induced or
aggravated by opioids” (Mauermann et al., 2015, p. 460). This differentiation is
important because with tolerance, an increase in opioid dosage will alleviate painful
symptoms whereas with opioid-induced hyperalgesia, an increased dose of opioids will
intensify painful symptoms.
Evidence of Hyperalgesia Versus Tolerance. In a randomized control trial,
Guignard et al., (2000) found that intraoperative remifentanil increased pain scores and
morphine requirements within the first 24 hours postoperative. They studied 50 adult
patients undergoing major abdominal surgery, who all received general anesthesia with
the volatile anesthetic desflurane, as well as a remifentanil drip. Participants were then
separated into two groups, with one group receiving high dose remifentanil and low
concentration of desflurane to maintain sedation, and the other group received low dose
remifentanil and high concentration of desflurane to maintain sedation. Guignard et al.,
(2000) found that the group receiving high dose remifentanil reported significantly higher
pain scores in the 24-hour postoperative period and required opioids earlier and more
frequently than the group receiving low dose remifentanil. At this time, these researchers
attributed this phenomenon to acute opioid tolerance, but suggested that further research
was needed into the phenomenon of opioid-induced hyperalgesia and the involvement of
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the NDMA receptor. Guignard et al., (2000) noted that it was difficult to differentiate
between tolerance and hyperalgesia in their patient population but found the patients in
their study did not report lower pain scores despite increasing doses of opioids in the
postoperative period, which is consistent with hyperalgesia.
Fletcher and Martinez (2014) performed a systematic review and meta-analysis of
27 randomized control trials (RCTs) which included a total of 1494 patients in an attempt
to explore the potential consequences of different doses of intraoperative opioids on
patient’s perceptions of pain intensity in the postoperative phase. Fletcher and Martinez
(2014) conducted this systematic review in accordance with the Prisma Statement and the
Cochrane Collaboration’s recommendations for assessing risk of bias in the RCTs they
selected. The authors asserted that this was the first quantitative systematic review and
meta-analysis to examine the impact of opioid-induced hyperalgesia in the postoperative
phase (Fletcher & Martinez, 2014). The primary outcome of this systematic review was
to investigate acute pain at rest 24 hours postoperatively as reported by patients using the
numerical rating scale (NRS). Secondary outcomes were identified as opioid
consumption in the 24-hour postoperative period, pain intensity as reported by patients on
a NRS at 1 hour and 4 hours postoperatively, and incidence of hyperalgesia measured
after the operation. Fletcher and Martinez (2014) measured and quantified the
phenomenon of primary and secondary hyperalgesia regarding surgical wounds of these
patients, describing primary hyperalgesia as the measurable pain threshold experienced
close to the wound, and secondary hyperalgesia as allodynia extending around the
wound.
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Fletcher and Martinez (2014) evaluated RCTs conducted between 1994 and 2013
that included adults and children receiving opioids for a variety of different surgical
procedures. The investigators identified their control group as patients receiving low
dose opioids intraoperatively and the experimental group as receiving high dose opioids
intraoperatively. Fletcher and Martinez (2014) found that at 1 hour, 4 hours, and 24
hours postoperatively, the experimental group reported higher pain scores in the 17 of the
RCTs (863 patients). They acknowledged that they were unable to differentiate between
tolerance and hyperalgesia when looking at total opioid intake in 24 hours, making the
validity of their results questionable. Five of the RCTs (471 patients) they examined
explored the phenomenon of primary and secondary hyperalgesia. No significant
difference was found in secondary hyperalgesia between the experimental and control
groups, but the incidence of primary hyperalgesia was found to be more pronounced in
the experimental group (Fletcher & Martinez, 2014). Despite insufficient evidence,
Fletcher and Martinez (2014) suggest that lower dose intraoperative remifentanil
administration can aid in more positive perceptions of pain postoperatively.
Mauermann et al., (2015) recognized a gap in the literature regarding opioidinduced hyperalgesia relating specifically to fentanyl administration. They performed a
prospective, double-blind RCT examining this issue. Since a great deal of literature
already acknowledges that remifentanil induces hyperalgesia in multiple animal and
human studies Mauermann et al., (2015) sought to examine the effect of fentanyl on acute
pain, hyperalgesia, and allodynia in healthy adults. Researchers defined healthy adults as
having ASA scores of I or II and BMI between 18 to 25 kg/m2. They excluded
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individuals who had a substance abuse history, psychiatric disorders, known or suspected
liver/kidney disease, and sleep apnea (Mauermann et al., 2015).
Mauermann et al., (2015) obtained written informed consent from 21 healthy
male volunteers, 20-39 years old, who were separated into two groups using a virtual coin
toss which ensures randomization of these groups. Both groups were familiarized with
the NRS pain scale for purposes of participating in this RCT. One group received high
dose fentanyl (10μg/kg) and one group received low dose fentanyl (1μg/kg) which were
administered in a consistent way using the same medication pump for all subjects.
Two models were used to elicit a pain response: Intradermal Electrical
Stimulation (IES) and Cold Pressor Pain (CPP). Mauermann et al., (2015) describes the
ability of IES to measure a hyperalgesic response by activating the C fibers, previously
described by Helms and Barone, through electrical stimulation of needles in the arm.
Allodynia was assessed by researchers using a cotton swab on the arm. Acute pain
response was measured in this study using CPP, which involves subjects holding their
arm in ice water and measuring the time in seconds it took for the subject to remove their
arm from the ice water. Opposite arms were used in this RCT in order to maintain
validity of results (Mauermann et al., 2015).
Mauermann et al., (2015) found that the group receiving high dose fentanyl
experienced lower levels of acute pain four to six hours after administration as compared
to the group receiving low dose fentanyl. However, the group treated with high dose
fentanyl had a greater incidence of hyperalgesia than the group treated with low dose
fentanyl. There was no significant difference between the groups when reporting
incidence of allodynia (Mauermann et al., 2015). Researchers concluded that more
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research needed to be performed on this topic because this is one of the first studies to
show opioid-induced hyperalgesia from fentanyl in healthy subjects.
Treatment and Prevention of Opioid-Induced Hyperalgesia
Researchers have recognized opioid-induced hyperalgesia as a phenomenon
existing within the concept of abnormal pain perception; however, treatment modalities
and prevention of it are still being researched. N-methyl-D-aspartate (NMDA) receptors,
which are found in nerve cells, are believed to be connected with hyperalgesia and the
“functionality of opioid receptors” (Jamero et al., 2011) because they acts as receptors for
the excitatory neurotransmitter, glutamate, which is released when individuals are
exposed to painful stimuli. The activation of NMDA receptors causes increased
sensitivity to pain and perception of pain while also decreasing the effectiveness of
opioid receptors (Jamero et al., 2011). NMDA antagonists such as ketamine can block
the NMDA receptor, which in turn has been thought to decrease hyperalgesic responses
by many researchers.
Ketamine. Ketamine is a noncompetitive N-methyl-d-asparate (NMDA) receptor
antagonist and derivative of phencyclidine (PCP) that causes dissociative anesthesia,
amnesia, and analgesia (Flood et al., 2015). Primary uses of ketamine involve its use as
an induction agent for anesthesia as well as an adjuvant medication for multimodal pain
control in the perioperative period (Nagelhout & Plaus, 2014). Activation of the NMDA
receptor through binding to glutamate is thought open a cation channel, causing an influx
of calcium, which in turn causes upregulation of second messengers such as cAMP
(Nagelhout & Plaus, 2014). Activation of the NMDA receptor has been linked to
disorders of pain such as hyperalgesia, phantom limb pain, and neuropathic pain
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(Nagelhout & Plaus, 2014; Urman et al., 2016). Ketamine prevents activation of the
NMDA receptor by suppressing the presynaptic release of the excitatory
neurotransmitter, glutamate (Flood et al., 2015; Nagelhout & Plaus, 2014). By blocking
the NMDA receptor, ketamine may prevent cations from entering the channel, reducing
central sensitization and chronic pain states (Urman et al., 2016).
Célèrier et al., (2000) were one of the first groups of researchers to examine the
effects of ketamine on opioid-induced hyperalgesia. They performed a randomized
crossover trial to test fentanyl’s effect on inducing hyperalgesia in rats. They also studied
the effects of ketamine administered alone and in conjunction with fentanyl on
nociceptive threshold in these rats. Célèrier et al., (2000) performed two sets of
experiments on six groups of adult male Sprague-Dawley rats who all weighed the 350400g. All rats being the same weight and same species added to the validity of the
results. Researchers conducting this RCT thoroughly described the consistency in
handling the rats and the controlled environment of these rats in the weeks leading up to
the experiment as well as the randomization of the rats (Célèrier et al., 2000).
The first set of experiments Célèrier et al., (2000) conducted involved splitting the
rats into six groups with 8-12 rats per group. The control group was given a placebo of
saline while the five experimental groups were given subcutaneous weight-based doses of
fentanyl every fifteen minutes at 20μg/kg, 40μg/kg, 60μg/kg, 80μg/kg, and 100μg/kg for
five days. The researchers examined the long-lasting effects of fentanyl on the rats’ pain
threshold based on the fentanyl dose received (Célèrier et al., 2000). They measured
these results using a modified version of the Randall-Selitto tool known as a paw pressure
vocalization test which applies a constant pressure to the hind paw of the rat until they
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squeak. Célèrier et al., (2000) found that on day zero, the increased dose of fentanyl
provided the rats with increased analgesia for the acute pain experienced. Conversely, in
days 1-5, researchers found that the rats that received higher doses of fentanyl had a
hyperalgesic response.
In the second set of experiments, Célèrier et al., (2000) tested the pain threshold
of the rats of one group that were pretreated with ketamine prior to administration of the
four consecutive doses of 60μg/kg of fentanyl for five days. The control group was
treated with ketamine and saline which provided no analgesic effect to the rats when
administered without opioids (Célèrier et al., 2000). Researchers found that the addition
of ketamine with the middle range dose fentanyl enhanced the analgesic effect and
prevented fentanyl-induced hyperalgesia (Célèrier et al., 2000). Though these results
yielded a positive outcome for prevention of hyperalgesia with ketamine, it is difficult to
generalize the results for humans due to the fact that rats participated in the study. The
small sample sizes of rats included in the study also undermine the validity of the results
and further research should be performed on humans before recommendations can be
made.
Hadi, Al Ramadani, Daas, Naylor, and Zelko, (2010) performed a prospective,
double blind, randomized control trial to determine if intraoperative ketamine combined
with opioids, compared with intraoperative opioids, alone would provide better
postoperative pain control for patients after a spinal fusion. The authors examined these
effects on 30, ASA I-II, healthy male and female patients and divided them into two
groups (n=15). Group 1 (G1) was given a remifentanil infusion at a dose of 0.2
mcg/kg/min and group 2 (G2) was given a remifentanil infusion at a dose of
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0.2mcg/kg/min plus a ketamine infusion at a dose of 1 mcg/kg/min. Hadi et al., (2010)
recorded and compared intraoperative vital signs, including mean arterial pressure (MAP)
every five minutes for each patient as well first pain scores, time (minutes) to first dose of
postoperative opioid, and total consumption of opioids (morphine) within the first
twenty-four hours after surgery. The intraoperative heart rate and MAP were
significantly higher (p < 0.05) in G2, compared with G1. The mean time to first
postoperative opioid consumption for G1 was 19.5 ± 3.2 minutes compared to G2 which
had a mean time of 22.9 ± 3.5 minutes, indicating a significantly (p < 0.05) later time to
first opioid in G2 compared with G1. The number of patients who reported pain after
surgery in G1 was 13/15, while G2 had 5/15 patients report pain after surgery which were
significant results (p < 0.05). Opioid consumption for the first 24 hours postoperatively
were 60mg of morphine in G1 and 45mg of morphine in G2, indicating significantly (p <
0.05) lower doses of postoperative morphine consumption in the group who received low
dose intraoperative ketamine with remifentanil. Hadi et al., (2010) concluded that their
results showed benefits to utilization of intraoperative ketamine in reducing pain scores
and opioid consumption in the postoperative period and suggested that ketamine may be
considered a routine anesthetic for spinal fusions in the future.
In 2011, Forero, Chan, and Restrepo-Garces performed a retrospective case report
on one patient’s experience with chronic lower back pain. They described the patient as a
52-year-old male with chronic pain issues lasting more than 20 years. His pain was first
treated conservatively with medical management and then with surgical intervention
where he received an L5-S1 laminectomy. He continued to experience back pain and
was again treated conservatively with different analgesic medications for another eleven
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years before he finally received an intrathecal pain pump (ITP). The ITP delivered
opioid analgesics with different medications such as morphine and hydromorphone at
varying doses throughout the years. Pain relief was still not achieved despite all
interventions and treatment modalities. He finally underwent a spinal cord stimulation
(SCS) procedure five years after the ITP was placed, however, his pain persisted. In
October of 2008, the patient complained of a new onset of burning and excruciating (9/10
on NRS) systemic pain and severe nausea. The integrity of the ITP was examined
through fluoroscopy and an invasive surgical exploration; however, the pump was intact,
and no malfunction was appreciated. The patient then began experiencing severe leg
spasms in addition to the generalized aches and burning sensation and received no relief
with increasing, high dose opioids. Physicians suspected opioid toxicity and opioidinduced hyperalgesia and they administered an intrathecal dose of ketamine. According
to the case report, one minute after administering this ketamine bolus, the patient reported
resolution of all painful symptoms. A maintenance infusion of intrathecal ketamine
along with a low dose opioid, 25% of the dose he was previously receiving, was started
with sustained relief of painful symptoms for this patient (Forero et al., 2011).
Although Forero et al., (2011) formulated thoughtful research in attempts to
explore ketamine’s role in reversal of opioid-induced hyperalgesia, the results cannot be
easily generalized because they are describing one patient’s experience. This patient had
specific attributes as he was a middle-aged male with many unknown factors such as
race, weight, and comorbidities which could all impact the results in different
populations. This case study also only evaluates intrathecal opioid and ketamine use,
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whereas all of the RCTs performed in humans describe intravenous use of opioids and
ketamine. It is unclear how the results would vary based on the route of administration.
This review of the literature has produced information regarding the effects of
ketamine as a potential treatment to reduce the incidence of opioid-induced hyperalgesia;
however, there is still a great deal of research to be done on the subject before
recommendations can be made for implementing treatment modalities for patients in the
perioperative phase. This topic is relevant in not only aiding in proper treatment of
patients, but also educating healthcare providers in recognizing differences between
opioid tolerance and opioid-induced hyperalgesia. Ongoing and prospective research of
this topic will guide practice changes for the future.
The theoretical framework that guided this research project will be presented next.
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Theoretical Framework
The theoretical framework that guided this systematic review was the Gate
Control Theory of Pain which evolved over time into the Neuromatrix Theory of Pain.
Specificity Theory of Pain
Throughout history there have been many pain theories proposed to describe the
complex nature of pain and pain perception. French philosopher, Rene Descartes,
proposed the Specificity Theory of Pain as early as 1644 (Helms & Barone, 2008). He
suggested that pain is a sensation produced by peripheral nerve impulses as a result of
injury and that peripheral pain receptors transmit pain via a straight line channel to the
brain (McAllister, 2014). Descartes viewed pain sensation and perception as a
phenomenon that directly correlates with the extent of the injury. This early Cartesian
pain theory does not account for differences in pain perception among diverse
populations or for phenomena such as chronic pain and phantom limb pain.
Gate Control Theory of Pain
Canadian psychologist Ronald Melzack and British neuroscientist Patrick Wall
recognized the shortcomings of Descartes’ Specificity Theory of Pain and proposed the
Gate Control Theory of Pain in 1965 which encompassed the physiologic as well as
emotional responses of pain (Melzack & Wall, 1965). Melzack first realized that pain
was both a physiologic and psychological phenomenon while working toward his Ph.D.
at McGill University in the 1950s, studying phantom limb pain (McAllister, 2014). The
Gate Control Theory of Pain suggests that a nerve gate exists in the spinal cord to allow
or prohibit pain signals to reach the brain. If the gate is open, the nerve impulses are able
to reach the brain and the sensation of pain is perceived (Melzack & Wall, 1965).
Conversely, if the gate is closed, nerve impulses do not reach the brain, resulting in
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decreased pain perception (Helms & Barone, 2008). The Gate Control Theory of Pain
shifted the focus away from the outdated Cartesian view of pain as a strictly peripheral
process to the central nervous system as a major regulator of pain perception (Melzack &
Wall, 1965).
According to the Gate Control Theory, A nerve fibers and C nerve fibers are
responsible for the transmission and sensation of pain along an afferent pathway from the
spinal cord to the brain. The pain impulses travel to the substantia gelatinosa in the
dorsal horn of the spinal cord where the gate is located, and it will either block or
facilitate pain impulses to the brain (Melzack & Wall, 1965; McEwen & Wills, 2014).
Wind-up Phenomenon
The Gate Control Theory relates directly to the central sensitization phenomenon
which can lead to abnormal processing of sensory information, resulting in hyperalgesia
(Dickenson, 2002). Dickenson (2002) described how after a tissue or nerve injury,
calcium channels within the spinal cord become activated. These active calcium
channels are responsible for the release of the excitatory neurotransmitter glutamate in
the A and C nerve fibers. NMDA receptors become activated when glutamate is released
causing the wind-up and central sensitization phenomena (Dickenson, 2002).
Melzack and Wall describe this wind-up phenomenon in the Gate Control Theory
as repeated and persistent stimulation of the C fibers, causing an intensified pain response
(Melzack & Wall, 1965). Helms and Barone (2008) make an analogy to describe this
phenomenon by comparing it to winding up a child’s toy; the more the toy is wound up,
the faster and longer it will run. The wind-up phenomenon is thought to be a major factor
in the abnormal pain response, hyperalgesia (Dickenson, 2002).
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Neuromatrix Theory of Pain
In 1999, Melzack and Walls evolved the Gate Control Theory of Pain into the
Neuromatrix Theory of Pain as a new and improved pain theory to clarify the unanswered
questions within the Gate Control Theory regarding “chronic pain issues, sex-based
differences, stress effects, and the effects of previous pain experiences” (Melzack &
Wall, 1965). The Neuromatrix Theory expands on the Gate Control Theory’s idea that
the central nervous system is more than just a passive receiver of pain signals from the
peripheral nervous system (McAllister, 2014). According to the Neuromatrix Theory,
each person has a unique “body-self neuromatrix” which is composed of neurons affected
by all aspects of the individual including their “physical, psychological, and cognitive
makeup, as well as his or her experience” (Helms & Barone, 2008). The Neuromatrix
Theory shifts the idea that the sensation of pain is elicited from the peripheral site of
tissue damage to a more abstract concept that involves the central nervous system,
composed of the brain and spinal cord, as the main producer of pain responses
(McAllister, 2014).
Clinical Relevance of the Gate Control Theory
The Gate Control Theory of Pain has been used as a theoretical framework for
many research studies because of its high potential for generalizability regarding its
applicability towards many different types and perceptions of pain. It can be used to
frame current pain research in different populations regarding age, gender, and disease
processes contributing to painful experiences.
Lane and Latham (2009) conducted a qualitative review of different studies
detailing the gaps in current literature regarding acute and chronic pain control using heat
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and cold therapy in children. Their nursing study references the Gate Control Theory
while discussing the mechanism of heat and cold therapy. They found that superficial
heating and cooling of tissue with ice packs or hot packs can stimulate thermoreceptors
deep within the tissues that can close the pain gate in the spinal cord and reduce pain
perception. Lane and Latham (2009) found that their ice packs work best on targeting A
nerve fibers and the hot packs works best on targeting C nerve fibers as pain control
strategies. Heat works best on the C nerve fibers because it promotes vasodilation while
decreasing the sympathetic nervous system’s response of releasing pain provoking
neurotransmitters such as bradykinin and prostaglandin as described in the Gate Control
Theory (Lane & Latham, 2009). Use of the Gate Control Theory in regard to treatment
and prevention of children’s acute and chronic pain is an example of the generalizability
of this pain theory.
Ngamkham, Holden, and Wilkie (2011) provide another example of utilization of
the Gate Control Theory of Pain in their comparative, secondary data analysis examining
the differences in pain patterns among 762 adult outpatients with cancer. The Gate
Control Theory framed their study as they analyzed cancer pain as a multidimensional
experience that differs from patient to patient regarding quality, location, and intensity of
pain. This pain theory acknowledges the complexities in pain perception including its
“sensory, affective, cognitive, and behavioral dimensions” (Ngamkham et al., 2011, p.
229).
The Gate Control Theory of Pain has changed not only the way healthcare
providers and researchers think about pain perception, but also the way pain is prevented
and treated. It is now believed that premedication with analgesic medication will keep
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the gate closed for longer, allowing fewer pain impulses to travel along the afferent
pathway to the brain (McEwen & Wills 2014). Keeping the gate closed will allow fewer
nerve impulses to reach the brain and the key focus of pain therapy involves preventing
pain before it happens to help keep the gate closed. The concepts of pain management
and prevention outlined in Gate Control Theory have shaped the way pain is currently
recognized and treated across a variety of patient populations suffering from different
types of pain.
The wind-up phenomenon described by Melzack and Wall (1965) is directly
involved in central sensitization because it leads to an amplified and abnormal pain
perception known as hyperalgesia, resulting from overstimulation of C fibers. Initially,
when opioids are administered, they act as agonists on opioid receptors which activate Gproteins, leading to inhibition of adenylyl cyclase and decreased cAMP, which produces
analgesia (Flood et al., 2015). Although the exact mechanism is still unclear, it is now
recognized that in high doses, opioids can induce a hyperalgesic pain response by
damaging C fibers through activation of the NMDA receptor by the release of glutamate
and activation of adenylyl cyclase which increases pronociceptive activity by increasing
levels of cAMP (Hayhurst & Durieux, 2016). The Gate Control Theory of Pain and
Neuromatrix Theory of Pain will be used to shape this systematic review by examining
the potential treatment and reduction of opioid-induced hyperalgesia, caused by the
central sensitization and wind-up phenomena, through the use of the NMDA antagonist,
ketamine.
Next, the methodology of this systematic review will be presented and discussed.
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Methods
Purpose
The purpose of this systematic review is to examine the effect of ketamine, on
reducing the phenomenon of opioid-induced hyperalgesia. Further research of this topic
will lead to clinical changes in the way pain is treated and prevented in the perioperative
phase.
Search Strategy
A comprehensive literature search was conducted using databases and websites
including MEDLINE, PubMed, CINHAL, Up-to Date, and Google Scholar. Current
research regarding the effect of ketamine on opioid-induced hyperalgesia was found after
performing a search for the keywords, “physiology of pain”, “hyperalgesia”, “opioidinduced hyperalgesia”, “fentanyl”, “remifentanil”, “ketamine”, “prevention”, and
“treatment”. The initial comprehensive search of current literature yielded over 150
potential articles on this topic from these databases. Studies were then limited to include
publications written in English within the past 18 years. Further narrowing of the search
provided articles that examined the use of ketamine on adult subjects (over the age of 18)
regarding treatment or prevention of opioid-induced hyperalgesia.
PRISMA Statement
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) Statement was used to frame this systematic review. The PRISMA Statement
incorporates a 27-item checklist and flow diagram aimed at improving the quality of the
systematic review by providing the reader with transparency and clarity of the studies
examined for purposes of this review (Hutton et al., 2015). By ensuring meticulousness
of the findings of this systematic review, validity of the results were elevated. The
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PRISMA checklist (Appendix A) and flow diagram (Appendix B) enhanced this
systematic review by addressing limitations and risk of bias within the studies used for
this review (Moher et al., 2017).
Inclusion/Exclusion Criteria
Inclusion criteria for this systematic review included meta-analysis, systematic
reviews, and randomized control trials conducted over the past 18 years that examine the
use of ketamine in male or female adult patients, over the age of 18, undergoing surgery.
The phenomenon of hyperalgesia must be measured within the immediate postoperative
phase.
Articles examined in this systematic review included patients who are relatively
healthy, with no severe or moribund comorbidities, which is measured for the purposes of
this review on the American Society of Anesthesiology (ASA) scoring system. ASA
scores of I indicate a completely healthy patient with no comorbidities. ASA scores of II
indicates the patient has a mild systemic disease or includes any individual who smokes.
ASA score of III indicates presence of a severe systemic disease that is not imminently
incapacitating or any morbidly obese patient regardless of age. ASA scores of IV
indicates that the patient has comorbidities that are incapacitating or an immediate threat
to their life. ASA scores of V indicate severe systemic disturbances within a patient who
is not expected to live more than 24 hours without surgical intervention (Daabiss, 2011).
Patients must be ASA score of I-III to be included in this study.
Exclusion criteria for this systematic review included any studies involving the
pediatric population and studies that were more than 18 years old. Other exclusion
criteria involved using articles that explore the use of other NMDA antagonist
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medications such as memantine, amantadine, methoxetamine, nitrous oxide, and
dextromethorphan in managing opioid-induced hyperalgesia (Jamero et al., 2011). Using
this inclusion and exclusion criteria, six randomized control trials were chosen in
performing this systematic review.
Data Collection
The randomized control trials that were chosen for this systematic review were
appraised and relevant data was collected and analyzed. In order to examine the effects
of ketamine on reducing opioid-induced hyperalgesia in adult surgical patients in the
perioperative period, tables were created for ease of comparison and analysis of different
variables in each study (Table 1 and Table 2). Table 1 reports data regarding
demographics of the studies, while Table 2 reports results of the outcomes measured in
the studies. Variables being examined have been collected and organized into the tables.
Some of these outcomes being reported include pain scores at designated times
throughout the postoperative period, quantity of analgesic medication used in the PACU,
and time to first postoperative opioid consumption. Evidence of hyperalgesia has been
measured and reported as well.
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Table 1
Data Collection Sheet #1
Study Title
Aim
Design
Sample
ASA Score
Methods
Outcomes
Measured
Table 2
Data Collection Sheet #2
Study Title
Intraoperative Opioid &
Ketamine Doses
Postoperative Pain
Score

1 hour – (pain score)
6 hour – (pain score)
24 hour – (pain score)

Evidence of
Hyperalgesia
Time to First
Postoperative Opioid
Administration (min)
Postoperative Analgesic
Consumption

Critical Appraisal Tool
Critical appraisal of the studies used for this systematic review were performed
using the Critical Appraisal Skills Programme (CASP). The CASP appraisal tool
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involves the use of multiple checklists that examines the usefulness and validity of the
studies chosen for this systematic review. Utilizing CASP checklists (Figure 1) to
evaluate the relevance and reliability of randomized control trials used for this systematic
review promotes trustworthiness of the findings (CASP, 2017).
Figure 1: CASP Randomized Control Trial Checklist (CASP, 2017)
1. Did the trial address a clearly focused issue?

YES

CAN’T
TELL
CAN’T
TELL
CAN’T
TELL

NO

2. Was the assignment of patients to treatments
randomized?
3. Were all of the patients who entered the trial
properly accounted for at its conclusion?

YES

4. Were patients, healthcare workers, and
personnel ‘blind’ to treatment?

YES

CAN’T
TELL

NO

5. Were groups similar at the start of the trial?

YES

NO

6. Aside from the experimental intervention,
were the groups treated equally?
7. How large was the treatment effect?
8. How precise was the estimate of the
treatment effect?
9. Can the results be applied in your context?

YES

CAN’T
TELL
CAN’T
TELL

10. Were all clinically important outcomes
considered?
11. Are the benefits worth the harm and cost?

YES

YES

YES

YES

CAN’T
TELL
CAN’T
TELL
CAN’T
TELL

NO
NO

NO

NO
NO
NO

Data Synthesis & Cross Study Analysis
The results from relevant studies have been evaluated, analyzed, and presented
using multiple tables to display the findings. Data was gathered, and placed into a table
for comparison, and a cross study analysis was performed (Table 3). This cross study
analysis evaluated the relationship between the dose of intraoperative opioids, whether or
not ketamine was administered and at what dose, pain scores at different points in the
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postoperative period, evidence of hyperalgesia, time to first postoperative opioid
administration, and total dose of postoperative opioid consumption within 24 hours.
Recommendations for future practice changes have been made based on statistically
significant findings within the research.
Table 3
Cross Study Analysis
Study

Intraoperative Opioid
& Ketamine Doses

Next, the results will be discussed.

Evidence of
Hyperalgesia

Results
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Results
The previously mentioned inclusion and exclusion criteria as well as the PRISMA
flow diagram (Appendix B) aided in the selection of five articles for purposes of this
systematic review. Initial searches yielded a total of 41 articles for potential use in this
systematic review. After reviewing the articles while referencing the PRISMA checklist
(Appendix A) to ensure quality of the selected articles as well as relevance to the topic of
this systematic review, 8 were selected for further appraisal. Closer examination of these
articles with the outlined inclusion and exclusion criteria and CASP checklist (Appendix
E) produced a total of 5 articles that incorporated the multifaceted outcomes investigated
to compile relevant, strong, and valid evidence for this systematic review.
Joly et al., (2005) conducted a double-blind RCT to examine if high-dose
remifentanil can induce hyperalgesia and assess the preventative effects of intraoperative
ketamine on remifentanil-induced hyperalgesia in healthy adults undergoing major
abdominal surgery. Researchers hypothesized that patients receiving high dose
intraoperative remifentanil would have an increased nociceptive threshold, which would
be indicative of hyperalgesia. They proposed this phenomenon could be counteracted
and prevented by administering ketamine in conjunction with remifentanil
intraoperatively according to the researchers (Joly et al., 2005).
The authors selected 75 patients with similar demographics undergoing major
abdominal surgery and separated them randomly into three groups of 25 (Appendix C.1,
Data Collection Sheet #1). Group 1 (n=25) received low dose remifentanil (0.05μg/kg)
intraoperatively plus a saline placebo infusion; group 2 (n=25) received high dose
remifentanil (0.4μg/kg) intraoperatively plus a saline placebo infusion; group 3 (n=24)
received high dose remifentanil (0.4μg/kg) in conjunction with 0.5 mcg/kg bolus of
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ketamine on induction of anesthesia and a 5 mcg/kg/min infusion of ketamine
intraoperatively until skin closure, and then 2 mcg/kg/min infusion of ketamine for 48
hours postoperatively (Joly et al., 2005).
Postoperative pain scores measured with a VAS were assessed and recorded by
PACU nurses every 15 minutes for the first hour, hourly for the following 3 hours, and
every 4 hours for the remaining 44 hours. Joly et al., (2015) found no significant
differences in postoperative pain scores at 24 or 48 hours after surgery among groups 1,
2, or 3.
Joly et al., (2005) examined time to first morphine consumption (min) and total
postoperative morphine consumption (mg) for the first 4 hours in PACU and up to 48
hours postoperatively. Researchers found no significant difference in the time to first
postoperative opioid administration among groups 1, 2, or 3. Total morphine
consumption (mg) in PACU did not significantly differ among any of the groups
(Appendix D.1, Data Collection Sheet #2), however; total postoperative morphine
consumption was significantly higher in group 2 who received intraoperative high-dose
remifentanil compared to groups 1 or 3 (Joly et al., 2005).
Extent of hyperalgesia was measured using von Frey hair number 16 (pressure =
122 g/mm2) adjacent to the surgical wound and an algometer was used to establish a pain
pressure threshold (kPa). Preoperative tactile pain thresholds (g/mm2) were similar
among the 3 groups. Measurements at 24 hours and 48 hours postoperative were
significantly higher in group 2 compared with groups 1 and 3 (p < 0.01). Extent of
hyperalgesia to von Frey hair number 16 was significantly higher in group 2, compared to
groups 1 and 3 (p < 0.05). Joly et al., (2005) concluded that large doses of intraoperative
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remifentanil generated a hyperalgesic response postoperatively and that this response was
prevented in the group that received ketamine in addition to large dose remifentanil (Joly
et al., 2005).
When evaluating this study using CASP (Appendix E.1, CASP Checklist) Joly et
al., (2005) adequately described the randomization process and accounted for variables
such as sex, age, weight, and length of surgery. These variables were considered by
researchers to be similar among their sample groups. The information allows the results
of their experiments to be potentially generalizable among patients receiving major
abdominal surgery. Postoperative pain was rated on a VAS and all participants were
familiarized with this scale prior to initiation the study. The PACU nurses treating the
patients in the postoperative phase were blinded to the group assignments and performed
frequent pain assessments which added to the validity of the results. All patients were
accounted for throughout the study and Joly et al., (2005) described how one patient was
excluded from this study after its initiation due to respiratory depression requiring
treatment with an opioid antagonist, naloxone.
Primary and secondary outcomes were clearly defined, assessed, and reported by
Joly et al., (2005). Reported limitations to their study involved the increased desflurane
requirement of the small-dose remifentanil group to maintain anesthesia throughout the
case. Researchers admit that because the phenomenon of opioid-induced hyperalgesia
and its implications are not well understood, more studies will have to be performed
before recommendations can be made regarding attenuation of the hyperalgesic response
with ketamine.
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Yalcin et al., (2012) used the research performed by Joly et al., (2005) as a
framework for their prospective, randomized control trial, comparing the effects of
paracetamol and ketamine on prevention of remifentanil-induced hyperalgesia (Appendix
C.2: Data Collection Sheet #1). Ninety patients undergoing a total abdominal
hysterectomy were divided into 3 groups. Group I (n=27) received 0.4 mcg/kg/min
infusion of remifentanil with a saline (placebo) infusion; group II (n=26) received 0.4
mcg/kg/min infusion of remifentanil with a ketamine infusion of 5 mcg/kg/min and a 0.5
mg/kg bolus of ketamine on induction of anesthesia; group III (n=26) received 0.4
mcg/kg/min infusion of remifentanil with an infusion of 1000 mg paracetamol over 15
minutes prior to induction of anesthesia (Yalcin et al., 2012). Researchers acknowledged
previous studies have shown that high dose remifentanil (0.4 mcg/kg/min) is associated
with inducing opioid-induced hyperalgesia and hypothesized that this effect could be
reduced with paracetamol and ketamine.
Yalcin et al., (2012) found that overall postoperative VAS pain scores were
significantly higher in group I compared to groups II and III (Appendix D.2: Data
Collection Sheet #2). There were no significant differences in postoperative VAS pain
scores between groups II and III. Researchers compared their findings of decreased
postoperative pain scores on VAS in the ketamine group to the lack of significant
findings regarding postoperative VAS pain scores in the research presented by Joly et al.,
(2005). Yalcin et al., (2012) deemed that appropriate timing of ketamine administration
in their study contributed to their results. Analgesic demand and morphine consumption
via PCA pump were evaluated and found to be significantly higher (p < 0.05) in group I
compared to groups II and III. Analgesic demand and morphine consumption via PCA
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pump were also found to be significantly higher (p < 0.05) in group III compared to
group II at 24 and 48 hours postoperatively (Yalcin et al., 2012).
Hyperalgesia was measured and quantified using a mean pressure pain threshold
(Lb) with a digital pressure algometer on the inner forearm and at the surgical incision
preoperatively, 24 hours postoperatively, and 48 hours postoperatively (Yalcin et al.,
2012). Baseline, preoperative values were similar among all three groups. Mean pain
pressure thresholds (Lb) at the surgical incision (Appendix D.2, Data Collection Sheet
#2) were found to be significantly lower (p < 0.05) in group I compared to groups II and
III. Group I was found to have a significantly lower (p < 0.05) pressure and pain
threshold compared to their baseline values at 24 and 48 hours postoperatively, indicating
a hyperalgesic response. Groups II and III had a significantly higher (p < 0.05) pain
pressure threshold at 24 and 48 hours postoperatively, indicating attenuation of the
hyperalgesic response with ketamine and paracetamol.
When evaluating this study using CASP (Appendix E.2, CASP Checklist), it was
found that the demographics of the three groups were comparable regarding sex, BMI,
ASA status, and comorbidities which increase the validity of researcher’s findings. All
participants of this study were women undergoing total abdominal hysterectomy which
may be a limitation for generalizability of these results for other types of surgeries or
patients who are male. Yalcin et al., (2012) described the randomization process of
patients and blinding of patients and health care providers. All participants of this study
were accounted for, with 11 being excluded due to “postoperative fever, duration of
surgery, and non-cooperation” (p. 329). Aside from the experimental interventions, all
groups were treated equally in their anesthetic administration, adding to the validity of
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the researcher’s results. Yalcin et al., (2012) concluded that both paracetamol and
ketamine, used in conjunction with high dose remifentanil were equally efficacious in
preventing opioid-induced hyperalgesia.
Choi et al., (2015) conducted a study modeled after the study conducted by Joly et
al., (2005) to compare the effects of high dose remifentanil, low dose remifentanil, and
high dose remifentanil given in conjunction with ketamine on postoperative pain scores,
postoperative opioid consumption, and postoperative incidence of hyperalgesia.
Researchers hypothesized that the addition of ketamine to remifentanil based anesthesia
would reduce the incidence of opioid-induced hyperalgesia. Choi et al., (2015) examined
75 patients undergoing laparoscopic gynecologic surgery and divided them into three
groups (Appendix C.3, Data Collection Sheet #1). Group RL (n=25) received a low dose
remifentanil infusion (0.05 mcg/kg/min); group RH (n=25) received a high dose
remifentanil infusion (0.3 mcg/kg/min); group KRH (n=25) received a high dose
remifentanil infusion (0.3 mcg/kg/min) with a 0.5 mcg/kg bolus of ketamine on induction
of anesthesia and a 5 mcg/kg/min infusion of ketamine during the procedure (Choi et al.,
2015).
Choi et al., (2015) found that postoperative pain scores reported on NRS were
significantly higher (p < 0.05) in group RH compared to groups RL and KRH (Appendix
D.3, Data Collection Sheet #2). There was no significant difference between time to first
postoperative opioid administration between the three groups, but postoperative fentanyl
(mcg) consumption was significantly higher (p < 0.05) in group RH compared to groups
RL or KRH. Postoperative ketorolac (mg) consumption was also measured and found to
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be significantly higher (p < 0.05) in group RH compared to groups RL or KRH (Choi et
al., 2015).
Hyperalgesia was measured adjacent to the wound by Choi et al., (2015)
preoperatively to obtain a baseline and at 24 hours postoperatively using a Touch-Test
sensory evaluation. Differences between the baseline value and 24 hour postoperative
value were evaluated, with a higher negative number being indicative of a hyperalgesic
response. Preoperative baseline values were similar among the three groups and 24 hour
postoperative Touch-Test sensory values were significantly lower (p < 0.05) in group RH
compared to groups RL or KRH. The difference was found to be significantly more
negative (p < 0.05) in group RH compared to groups RL and KRH, indicating a
hyperalgesic response in group RH (Choi et al., 2015).
When evaluating the RCT by Choi et al., (2015) using the CASP checklist
(Appendix F, CASP Checklist), it was determined that the aim of the study was clear.
Though patients were said to be randomized, researchers did not describe the
randomization process. Blinding was also not addressed by Choi et al., (2015) which
may alter the validity of their results. Researchers evaluated patient demographics such
as age, comorbidities, ASA status, BMI, baseline vital signs, and length of procedure and
found no significant difference between these variables which could increase validity and
generalizability of their results. They did not disclose the gender of their patients
included in this study which is a limitation for generalizability of their results. They
acknowledged a potential limitation of their research being that group RL received a
higher end-tidal concentration of desflurane to maintain appropriate anesthetic depth
compared to groups RH and KRH, but that there were no other differences in anesthetic
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management of these patients (Choi et al., 2015). Choi et al., (2015) concluded that
opioid-induced hyperalgesia was found to be reduced with the administration of ketamine
when providing remifentanil based anesthesia.
Leal et al., (2015) performed a prospective, double-blind, RCT to evaluate the
effect of intraoperative ketamine on reducing remifentanil-induced hyperalgesia
(Appendix C.4, Data Collection Sheet #1). Researchers separated 56 patients,
undergoing a laparoscopic cholecystectomy, into 2 groups. Group1 (n=28) received an
intraoperative remifentanil infusion at 0.4 mcg/kg/min in addition to a 5 mcg/kg/min
ketamine infusion, while group 2 received an intraoperative remifentanil infusion at 0.4
mcg/kg/min with a saline infusion (placebo) (Leal et al., 2015). Outcomes of their
research (Appendix D.4, Data Collection Sheet #2) show that postoperative pain scores
measured on NRS were significantly lower (p < 0.05) in group 1 compared to group 2
(Leal et al., 2015). No significant difference was appreciated in time to first
postoperative opioid administration or total 24 hour postoperative morphine consumption
(mg) between groups 1 and 2 (Leal et al., 2015).
Leal et al., (2015) measured hyperalgesia using Von Frey monofilaments and an
algometer at the thenar eminence and periumbilical region preoperatively and 24 hours
postoperatively to evaluate pain threshold. Significant differences (p > 0.05) in the
hyperalgesic response were observed at the thenar eminence in group 1 compared to
group 2, suggesting a potential reduction in secondary hyperalgesia. There were no other
significant differences between groups 1 and 2 using the Von Frey monofilaments or
algometer.
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Hyperalgesia was also estimated by evaluating cytokine levels, specifically
interleukin-6 (IL-6), interleukin-8 (IL-8), and interleukin-10 (IL-10), preoperatively, 5
hours after incision, and 24 hours after surgery by comparing differences in blood levels
(Leal et al., 2015). Researchers hypothesized that cytokine levels could be associated
with the development of hyperalgesia. According to Leal et al., (2015), IL-6 is a proinflammatory marker associated with the extent of tissue damage incurred during surgery.
Leal et al., (2015) also describes IL-8 as significant for recruiting neutrophils and is
associated with inflammation, while IL-10 is an anti-inflammatory marker shown in
previous studies to increase with administration of ketamine. Leal et al., (2015) found no
significant differences in IL-6, IL-8, or IL-10 levels preoperatively, 5 hours after incision,
or 24 hours postoperatively between groups 1 and 2.
When evaluating the RCT by Leal et al., (2015) using the CASP checklist
(Appendix E.4, CASP Checklist), it was determined that the aim of the study was clear.
The randomization and double-blinding process was thoroughly explained, adding to the
validity of these results. Researchers evaluated patient demographics such as age, sex,
comorbidities, ASA status, BMI, baseline vital signs, and length of procedure and found
no significant difference between these variables which could increase validity and
generalizability of their results. All participants in this study were accounted for and both
groups were given the same anesthetic, with the exception of the experimental group
receiving ketamine, which adds to the validity of the results. A limitation of this RCT is
that there is not enough evidence that certain inflammatory markers examined in this
study are undoubtedly indicative of a hyperalgesic response. More research needs to be
conducted before definitive conclusions can be drawn regarding the correlation between
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hyperalgesia and IL-6, IL-8, and IL-10. A strength of this RCT is that in addition to
inflammatory markers, Leal et al., (2015) also measured and evaluated primary and
secondary hyperalgesia using a Von Frey monofilament and algometer which have been
used to measure hyperalgesia in many other studies, increasing validity of these results.
Leal et al., (2015) concluded that there was no significant attenuation of the hyperalgesic
response induced by remifentanil with the addition of ketamine.
A prospective, randomized, double-blinded RCT was performed by Kido et al.,
(2019) to examine if low dose intraoperative ketamine prevents acute remifentanilinduced tolerance (Appendix C.5, Data Collection Sheet #1). Researchers included 40
patients, undergoing orthognathic surgery, and separated them into three groups. Group
RH (n=12) was given a high dose, remifentanil infusion at 0.6 mcg/kg/min; group RL
(n=12) was given a low dose, remifentanil infusion at 0.2 mcg/kg/min; group KRH was
given a high dose, remifentanil infusion at 0.6 mcg/kg/min in addition to a 0.5 mcg/kg
bolus of ketamine on induction of anesthesia with a 5 mcg/kg/min infusion of ketamine
throughout the case (Kido et al., 2019). Outcomes of their research (Appendix D.5, Data
Collection Sheet #2) show that no significant differences in postoperative VAS pain
scores were appreciated between any of the groups. Postoperative analgesic demand and
fentanyl (mcg/kg) consumption via a PCA pump were significantly higher in group RH
compared to groups RL (p < 0.05) and KRH (p < 0.01) (Kido et al., 2019).
Kido et al., (2019) tested the inflammatory markers C-reactive protein (CRP),
neutrophils, lymphocytes, and neutrophil to lymphocyte ration (NRL) which they
hypothesized to be associated with a hyperalgesic response. Researchers obtained
baseline blood samples preoperatively and again on postoperative day 1 (POD 1) and
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postoperative day 7 (POD 7). There were no significant differences in CRP levels or
neutrophil levels among any of the groups preoperatively, POD 1, or POD 7 (Kido et al.,
2019). Lymphocyte levels were significantly lower (p < 0.05) in group KRH on POD 1
compared to group RH while NLR levels were found to be significantly higher (p <
0.001) in group KRH on POD 1 compared to group RH and group RL (Kido et al., 2019).
Kido et al., (2019) concluded that high dose remifentanil was associated with increased
postoperative opioid requirements, a higher postoperative analgesic demand, and
hyperalgesia whereas administration of ketamine in conjunction with high dose
remifentanil anesthesia can decrease the incidence of opioid-induced hyperalgesia and
also decrease postoperative opioid requirements.
When utilizing the CASP checklist (Appendix E.5, CASP Checklist) to evaluate
this RCT, it was found that the trial addressed a clearly focused issue. The process of
randomization of participants and blinding of health care providers was described by
Kido et al., (2019), adding to the validity of their results. Patients included in this study
were similar regarding demographics, ASA status, and comorbidities, increasing
generalizability of these results to patients undergoing orthognathic surgery. All patients
were accounted for throughout this RCT, with one being excluded because of a
psychiatric illness and three being withdrawn due to the need for a second surgical
procedure (Kido et al., 2019). Several limitations were identified in this RCT including
the fact that the high dose of remifentanil is higher than what is typically used for
remifentanil based anesthesia, which is acknowledged by Kido et al., (2019). Another
limitation of this RCT is that there is not enough evidence that certain inflammatory
markers examined in this study are undoubtedly indicative of a hyperalgesic response.
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More research needs to be conducted to determine the correlation between inflammatory
markers and hyperalgesia as only one study, for example, has found that higher NLR
levels to be associated with decreased postoperative pain scores (Kido et al., 2019). The
relationship between these inflammatory markers and opioid-induced hyperalgesia needs
to be determined before definitive conclusions can be inferred (Kido et al., 2019). The
validity of the researcher’s speculations about hyperalgesia should be questioned because
they did not perform an assessment of hyperalgesia using Von Frey monofilaments and
algometers which have been accepted and used to assess primary and secondary
hyperalgesia in multiple other research studies.
Next, the summary and conclusions will be discussed.
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Summary and Conclusions
The phenomenon of hyperalgesia has been defined as an abnormal and intensified
response to a painful stimulus (Mauermann et al., 2015). As described throughout this
systematic review, hyperalgesia can be induced by chronic opioid administration, but can
also be induced by acute opioid administration, such as intraoperatively, in healthy,
opioid naïve individuals. Although the exact mechanism of opioid induced hyperalgesia
(OIH) is not fully understood, it is believed that both peripheral and central nociceptive
pathways are involved, and an imbalance of excitatory and inhibitory neurotransmitters
may be culpable in the occurrence of OIH. Agonism of the NMDA receptor by opioids
due to upregulation of pronociceptive, excitatory neurotransmitters such as substance P
and glutamate is believed to contribute to this phenomenon (Bottemiller, 2012).
Antagonism of the NMDA receptor with ketamine has been shown in multiple
randomized control trials included in this systematic review as an efficacious treatment
for reducing the incidence OIH, reducing postoperative pain scores, and reducing
postoperative opioid consumption.
The purpose of this systematic review was to examine the effect of ketamine, on
reducing the phenomenon of opioid-induced hyperalgesia. A literature review discussing
the physiology of pain, individual differences in pain perception, abnormal pain
responses, and pharmacological treatment of pain was completed. The theoretical
framework that guided this systematic review is the Gate Control Theory of pain which
later evolved into the Neuromatrix Theory of Pain, which encompasses both the physical
and emotional response to pain and how perception of pain may differ among individuals.
These theories describe the concepts of wind up and central sensitization which directly
correlate with hyperalgesia.
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In order to find randomized control trials suitable for use within this systematic
review, a comprehensive literature search was conducted using databases and websites
including MEDLINE, PubMed, CINHAL, Up-to Date, and Google Scholar. Current
research regarding the effect of ketamine on opioid induced hyperalgesia was found and
quality of the research was assessed using the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) Statement. The PRISMA Statement incorporates
a 27-item checklist (Appendix A, Prisma Checklist) and flow diagram (Appendix B,
Prisma Flow Diagram) aimed at improving the quality of the systematic review by
providing the reader with transparency and clarity of the studies examined for purposes
of this review (Hutton et al., 2015; Moher et al., 2017). By ensuring meticulousness of
the findings of this systematic review, validity of the results were elevated.
The randomized control trials that were chosen for this systematic review were
appraised using the Critical Appraisal Skills Programme (CASP) and relevant data was
collected and analyzed. The CASP appraisal tool involves the use of multiple checklists
that examined the usefulness and validity of the studies chosen for this systematic review.
Utilizing CASP checklists to evaluate the relevance and reliability of randomized control
trials used for this systematic review promotes trustworthiness of the findings (CASP,
2017).
In order to examine the effects of ketamine on reducing opioid-induced
hyperalgesia in adult surgical patients in the perioperative period, tables were created
(Appendix C, Data Collection Sheet #1 & Appendix D, Data Collection Sheet #2) for
ease of comparison and analysis of different variables in each study. Finally, a cross
study analysis (Appendix F, Cross Study Analysis) was performed which evaluated the
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relationship between the doses of intraoperative opioids, whether or not ketamine was
administered and at what dose, postoperative pain scores, evidence of hyperalgesia, time
to first postoperative opioid administration, and total dose of postoperative opioid
consumption.
This systematic review yielded mixed results regarding the benefits to utilization
of intraoperative ketamine to attenuate the incidence of OIH in the perioperative phase.
In three out of five of the randomized control trials examined for this systematic review,
groups that received ketamine in conjunction with high dose opioids had significantly
lower postoperative pain scores when compared with groups receiving high or low dose
opioids alone or with a placebo. Total postoperative opioid consumption was lower in
the group that received ketamine in four out of five studies, while time to first opioid
consumption produced statistically insignificant results in all five studies. Ketamine was
shown to attenuate the incidence of OIH in four out of five randomized control trials
assessed for purposes of this systematic review.
Mixed results in this systematic review regarding the ability of ketamine to
mitigate OIH in the perioperative phase may be due to several limitations encountered
while formulating this systematic review. There were limited randomized control trials
available that assessed all relevant aspects of the potential effects of using ketamine to
prevent OIH. Many prospective articles did not measure hyperalgesia, but only measured
the effect of ketamine on postoperative pain scores and total postoperative opioid
consumption, yielding them unusable for this systematic review. The articles selected for
this systematic review included a low number of participants, ranging from 40 total
participants to 90 total participants. Further studies with larger patient populations would
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add to the validity of these results. The types of surgeries evaluated in the randomized
control trials used for this systematic review varied immensely and therefore level of pain
elicited from these surgeries was inconsistent. This makes generalizability of the results
of these studies difficult. Lastly, the methods of evaluating hyperalgesia differed among
the selected randomized control trials. Some trials used an algometer to establish a pain
pressure threshold to evaluate primary and secondary hyperalgesia while other studies
evaluated hyperalgesia by measuring inflammatory markers. Inconsistencies in
measurement of hyperalgesia may invalidate the results. These limitations may skew the
veracity of the results and further, more comprehensive research is needed on this topic
before definitive conclusions can be made regarding attenuation of OIH with the use of
ketamine.
Recommendations and implications for advanced nursing practice will be
discussed next.
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Recommendations and Implications for Advanced Nursing Practice
Pain in the postoperative period is a serious issue that can have a negative impact
on patient outcomes. Poorly managed pain in the perioperative phase can result in
pathologic conditions such as deep vein thrombosis, pulmonary embolism, pneumonia,
and impaired wound healing (Apefelbaum, Chen, Mehta, & Gan, 2003). Pain can result
in emotional and psychological complications such as demoralization, insomnia, and
patient dissatisfaction (Apefelbaum et al., 2003). These postoperative complications can
result in extended length of stay in the hospital, hospital readmissions, as well as the
economic burden of continued treatment (Apefelbaum et al., 2003). Better management
of pain by the advanced practice nurse in the perioperative phase can result in better
patient outcomes, fewer postoperative complications, and increased patient satisfaction.
Bottemiller (2012) estimated that medical expenses related directly to medical or surgical
pain management along with indirect costs of lost workdays and decreased productivity
cost Americans approximately $635 billion per year. These staggering statistics reveal
the importance for advanced practice nurses to understand the complexity of pain so that
they may be better equipped to treat it.
The aim of this systematic review was to examine the effect of ketamine on
reducing the phenomenon of opioid-induced hyperalgesia (OIH). Recognition of OIH is
paramount because OIH may be easily mistaken for acute opioid tolerance. Since acute
tolerance and OIH have a similar clinical presentation, it is imperative for the advanced
practice nurse to differentiate between them. With acute opioid tolerance, an increase in
opioid dosage will alleviate painful symptoms whereas with OIH, an increased dose of
opioids will intensify painful symptoms. Treatment options for tolerance include
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increasing the dose of opioids and using a multimodal approach to pain management to
produce analgesia (Flood et al., 2015). Although overall results of the randomized
control trials included in this systematic review are mixed, there is a suggestion that the
use of ketamine may attenuate the incidence of OIH, reduce postoperative pain scores,
and reduce postoperative opioid consumption.
Further research is required before recommendation of the use ketamine for
treatment and prevention of OIH can be definitively made; however, results from this
systematic review suggest that pharmacological antagonism of the NMDA receptor with
ketamine is a viable option to manage this phenomenon, especially with remifentanil
based anesthesia. Although more extensive research on this topic is needed, utilization of
information from this systematic review may lead to a reduction in OIH and may result in
improved patient outcomes and patient satisfaction.
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Appendix A
PRISMA 2009 Checklist
Section/topic

# Checklist item

TITLE
Title

1

Identify the report as a systematic review, meta-analysis, or
both.

2

Provide a structured summary including, as applicable:
background; objectives; data sources; study eligibility criteria,
participants, and interventions; study appraisal and synthesis
methods; results; limitations; conclusions and implications of
key findings; systematic review registration number.

ABSTRACT
Structured
summary

INTRODUCTION
Rationale

3

Describe the rationale for the review in the context of what is
already known.

Objectives

4

Provide an explicit statement of questions being addressed with
reference to participants, interventions, comparisons, outcomes,
and study design (PICOS).

Protocol and
registration

5

Indicate if a review protocol exists, if and where it can be
accessed (e.g., Web address), and, if available, provide
registration information including registration number.

Eligibility
criteria

6

Specify study characteristics (e.g., PICOS, length of follow-up)
and report characteristics (e.g., years considered, language,
publication status) used as criteria for eligibility, giving rationale.

Information
sources

7

Describe all information sources (e.g., databases with dates of
coverage, contact with study authors to identify additional
studies) in the search and date last searched.

Search

8

Present full electronic search strategy for at least one database,
including any limits used, such that it could be repeated.

Study
selection

9

State the process for selecting studies (i.e., screening, eligibility,
included in systematic review, and, if applicable, included in the
meta-analysis).

METHODS

Data collection
process

10

Describe method of data extraction from reports (e.g., piloted
forms, independently, in duplicate) and any processes for
obtaining and confirming data from investigators.

Data items

11

List and define all variables for which data were sought (e.g.,
PICOS, funding sources) and any assumptions and
simplifications made.

Risk of bias in
individual
studies

12

Describe methods used for assessing risk of bias of individual
studies (including specification of whether this was done at the
study or outcome level), and how this information is to be used
in any data synthesis.

Summary
measures

13

State the principal summary measures (e.g., risk ratio,
difference in means).

Reported
on page
#
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Synthesis of
results

14

Describe the methods of handling data and combining results of
studies, if done, including measures of consistency (e.g., I2) for
each meta-analysis.

Risk of bias
across studies

15

Specify any assessment of risk of bias that may affect the
cumulative evidence (e.g., publication bias, selective reporting
within studies).

Additional
analyses

16

Describe methods of additional analyses (e.g., sensitivity or
subgroup analyses, meta-regression), if done, indicating which
were pre-specified.

Study
selection

17

Give numbers of studies screened, assessed for eligibility, and
included in the review, with reasons for exclusions at each
stage, ideally with a flow diagram.

Study
characteristics

18

For each study, present characteristics for which data were
extracted (e.g., study size, PICOS, follow-up period) and
provide the citations.

Risk of bias
within studies

19

Present data on risk of bias of each study and, if available, any
outcome level assessment (see item 12).

Results of
individual
studies

20

For all outcomes considered (benefits or harms), present, for
each study: (a) simple summary data for each intervention
group (b) effect estimates and confidence intervals, ideally with
a forest plot.

Synthesis of
results

21

Present results of each meta-analysis done, including
confidence intervals and measures of consistency.

Risk of bias
across studies

22

Present results of any assessment of risk of bias across studies
(see Item 15).

Additional
analysis

23

Give results of additional analyses, if done (e.g., sensitivity or
subgroup analyses, meta-regression [see Item 16]).

Summary of
evidence

24

Summarize the main findings including the strength of evidence
for each main outcome; consider their relevance to key groups
(e.g., healthcare providers, users, and policy makers).

Limitations

25

Discuss limitations at study and outcome level (e.g., risk of
bias), and at review-level (e.g., incomplete retrieval of identified
research, reporting bias).

Conclusions

26

Provide a general interpretation of the results in the context of
other evidence, and implications for future research.

27

Describe sources of funding for the systematic review and other
support (e.g., supply of data); role of funders for the systematic
review.

RESULTS

DISCUSSION

FUNDING
Funding
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Appendix B
PRISMA 2009 Flow Diagram

(Moher et al., 2017)
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Appendix C
Data Collection Sheet #1
Appendix C.1
Joly, V., Richebe, P., Guignard, B., Fletcher, D., Maurette, P., Sessler, D. I., & Chauvin, M. (2005). Remifentanil-induced
postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology, 103(1), 147-155.
doi:10.1097/00000542-200507000-00022
Aim

To examine if high-dose remifentanil can induce hyperalgesia and to assess if hyperalgesia can be prevented with low-dose ketamine

Design

Double-blind randomized control trial

Sample

75 patients undergoing major abdominal surgery
Preoperative pain scores on VAS*, tactile pain threshold, and baseline vital signs were comparable among all patients.
Surgical characteristics such as duration of surgery/anesthesia were similar among all patients.

ASA Score
Methods

Patients included had similar demographics and comorbidities and were 44-71 years old.
Patients were excluded if the surgical plan included keeping the patient intubated after surgery, they suffered from a chronic
inflammatory disease, they had a history of substance abuse, were chronic opioid users, they had a history of psychiatric disease or
cardiac disease that was a contraindication to ketamine administration, they did not understand how to self-administer opioids via a
PCA pump, or if they were obese.
I – III
75 patients were divided into 3 groups:
Group 1: Small-dose remifentanil (n=25): 0.05 mcg/kg/min remifentanil infusion plus a saline placebo infusion
Group 2: Large-dose remifentanil (n=25): 0.4 mcg/kg/min remifentanil infusion plus a saline placebo infusion
Group 3: Large-dose remifentanil + Ketamine (n=24): 0.4 mcg/kg/min remifentanil infusion with 0.5 mcg/kg bolus of ketamine and 5
mcg/kg/min infusion of ketamine until skin closure, then 2 mcg/kg/min x 48 hours postoperatively.
Morphine PCA* pump with no continuous dose, demand dose of 1 mg, with a 5 minute lockout was given to all patients 4 hours after
extubation.
Student t test, Fisher exact test, Kruskal-Wallis test, and Statview for Windows were used to measure and compare
statistical significance of the data.
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Outcomes
Measured

Morphine dose (mg) administered in PACU*
48 hour cumulative postoperative morphine (mg) requirement
Tactile pain threshold (g/mm2) preoperatively, 24 hours postoperatively & 48 hours postoperatively, 2-3 cm adjacent to the incision
measured with von Frey hair
Extent of hyperalgesia to von Frey hair number 16 (pressure = 122 g/mm2) 24 hours postoperatively and 48 hours postoperatively
VAS 24 hours postoperatively and 48 hours postoperatively
Algometer (kPa) measurement preoperatively, 24 hours postoperatively, and 48 hours postoperatively

*Note: VAS: Visual Analog Scale; PCA: Patient-controlled analgesia; PACU: Post-anesthesia care unit
(Joly et al., 2005)
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Appendix C.2
Yalcin, N., Uzun, S. T., Reisli, R., Borazan, H., & Otelcioglu, S. (2012). A comparison of ketamine and paracetamol for preventing
remifentanil induced hyperalgesia in patients undergoing total abdominal hysterectomy. International Journal of Medical
Sciences,9(5), 327-333. doi:10.7150/ijms.4222
Aim
Design
Sample

ASA Score

“To compare the effects of ketamine and *paracetamol on preventing remifentanil induced hyperalgesia” (p. 327)
Prospective randomized control trial
90* patients undergoing total abdominal hysterectomy
Preoperative pain scores on VAS* (0-10) were comparable among all patients.
Preoperative QST* pain pressure threshold with digital pressure algometer was comparable among all patients.
Surgical characteristics such as duration of surgery/anesthesia were similar among all patients.
Patients included were 35-70 years old.
Patients were excluded if they had a psychiatric history, inability to use a PCA* device, chronic pain disorders, cardiac
disorders, renal insufficiency, hematologic disorders, or if on chronic analgesics or opioid treatment. Patients were also
excluded the duration of surgery was greater than 120 minutes.
I – II
Patients were divided into 3 groups; group I, group II, group III

Methods
Group I (n=27): 0.4 mcg/kg/min remifentanil with saline infusion
Group II (n=26): 0.4 mcg/kg/min remifentanil infusion with ketamine infusion 5 mcg/kg/min and 0.5 mg/kg ketamine bolus
Group III (n=26): 0.4 mcg/kg/min remifentanil infusion with 1000 mg paracetamol infusion over 15 min pre-induction of
anesthesia

Outcomes
Measured

ANOVA and SPSS software were used to compare results from each group.
Pain scores reported on VAS 0, 2, 4, 6, 12, and 24 hours postoperatively
Analgesic delivery (morphine mg) via PCA at 2, 4, 6, 12, 24, and 48 hours postoperatively
Analgesic demand (PCA button pressed) at 2, 4, 6, 12, 24, and 48 hours postoperatively
Mean pressure pain threshold (Lb) preoperative, 24 hour hours postoperative, and 48 hours postoperative

*Note: Paracetamol = Acetaminophen; 11/90 patients excluded; QST: Quantitative Sensory Tests; VAS: Visual Analog Scale; PCA: Patient-controlled analgesic
(Yalcin et al., 2012)
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Appendix C.3
Choi, E., Lee, H., Park, H. S., Lee, G. Y., Kim, Y. J., & Baik, H. (2015). Effect of intraoperative infusion of ketamine on remifentanilinduced hyperalgesia. Korean Journal of Anesthesiology, 68(5), 476-480.
Aim
Design
Sample

ASA Score

To examine the effect of intraoperative ketamine on the incidence of remifentanil induced hyperalgesia
Randomized control trial
75 patients undergoing laparoscopic gynecologic surgery
Preoperative pain scores on NRS* were comparable among all patients.
Preoperative Touch-Test Sensory Evaluation threshold was comparable among all patients.
Surgical characteristics such as duration of surgery/anesthesia were similar among all patients.
Patients included were 23-60 years old.
Patients were excluded if they had a psychiatric history or substance abuse history.
I – II
75 patients were divided into 3 groups; RL, RH, and KRH

Methods
Group RL (n=25): 0.05 mcg/kg/min remifentanil infusion
Group RH (n=25): 0.3 mcg/kg/min remifentanil infusion
Group KRH (n=25): 0.3 mcg/kg/min remifentanil infusion with 0.5 mcg/kg bolus of ketamine and 5 mcg/kg/min infusion of
ketamine

Outcomes
Measured

ANOVA and Bonferoni post-hoc analysis using GraphPad Prism were used to compare results from each group.
Pain scores reported on NRS* 0, 1, 6, and 24 hours postoperatively
24 hour postoperative analgesic (ketorolac) requirement (mg)
48 hour postoperative fentanyl (mcg) requirement
Touch-Test Sensory Evaluation to examine hyperalgesia (preoperative, postoperative, and difference)

*Note: NRS: Numerical Rating Scale
(Choi et al., 2015)
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Appendix C.4
Leal, P. C., Salomão, R., Brunialti, M. K., & Sakata, R. K. (2015). Evaluation of the effect of
ketamine on remifentanil-induced hyperalgesia: A double-blind, randomized study. Journal of Clinical Anesthesia,27(4), 331337. doi:10.1016/j.jclinane.2015.02.002
Aim

To evaluate the effect of intraoperative ketamine on reducing remifentanil-induced hyperalgesia

Design

Prospective, double-blind, randomized control trial

Sample

56 patients undergoing laparoscopic cholecystectomy.
Preoperative evaluation of hyperalgesia using von Frey monofilaments was comparable among all patients.
Surgical characteristics such as duration of surgery/anesthesia were similar among all patients.

ASA Score
Methods

Outcomes
Measured

Patients included were ≥18 years of age, male or female, with similar demographics and comorbidities.
Patients were excluded if they had a psychiatric history, substance abuse history, if they had contraindications to selfadministering opioids via a *PCA pump, or if they were on chronic opioids or had taken opioids within 12 hours before
surgery.
I – II
56 patients were divided into 2 groups:
Group 1 (n=28): 0.4 mcg/kg/min remifentanil infusion with 5 mcg/kg/min ketamine infusion
Group 2 (n=28): 0.4 mcg/kg/min remifentanil infusion with saline infusion
SPSS 17 was used for sample size calculation and statistical analysis. Kolmogorov-Smirnov and Shapiro, Fisher exact test,
Mann-Whitney test, and Student t test were used to evaluate the data. CONSORT was used to outline the data collected and
used for this randomized control trial.
Pain scores reported on NRS* 1, 6, 12, and 24 hours postoperatively
Time to first postoperative supplemental morphine (min)
24 hour postoperative consumption of morphine (mg)
Evidence of hyperalgesia using 6 von Frey monofilaments and an algometer in the thenar eminence and periumbilical regions
(preoperative and 24 hours postoperative).
Serum levels of *IL-6, IL-8, & IL-10, preoperative, 5 hours after incision, and 24 hours postoperatively.

*Note: PCA: Patient-controlled analgesia; NRS: Numerical Rating Scale; IL: Interleukin
(Leal et al., 2015)
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Appendix C.5
Kido, K., Toda, S., Shindo, Y., Miyashita, H., Sugino, S., & Masaki, E. (2019). Effects of low-dose ketamine infusion on remifentanilinduced acute opioid tolerance and the inflammatory response in patients undergoing orthognathic surgery. Journal of Pain
Research,12, 377-385. doi:10.2147/jpr.s177098
Aim
Design
Sample

ASA Score
Methods

Outcomes
Measured

To examine if low dose intraoperative ketamine prevents acute remifentanil-induced tolerance
Prospective, randomized, double-blind study
40* patients undergoing orthognathic surgery
Preoperative pain scores on VAS* were comparable among all patients.
Surgical characteristics such as duration of surgery/anesthesia were similar among all patients.
Patients included were 18-41 years old.
Patients were excluded if they had a psychiatric disorder, chronic opioid use, obesity, a chronic inflammatory disease, or
acute cardiac disease.
I – II
40 patients were divided into 3 groups; RH, RL, and KRH
Group RH (n=12): 0.6 mcg/kg/min remifentanil infusion
Group RL (n=12): 0.2 mcg/kg/min remifentanil infusion
Group KRH (n=12): 0.6 mcg/kg/min remifentanil infusion with 0.5 mcg/kg bolus of ketamine and 5 mcg/kg/min infusion of
ketamine
G* power software, Kolmogorov-Smirnov test, Kruskal-Wallis test, Chi-squared test, and GraphPad Prism were used to
analyzed statistically significant results.
Pain scores reported on VAS 1, 3, 6, 12, and 24 hours postoperatively
24 hour postoperative analgesic delivery (fentanyl, mcg/kg) via PCA* pump
24 hour analgesic demand (PCA button pressed)
Inflammatory markers: CRP* (mg/dL), Neutrophils (x1000/µL), Lymphocytes (x1000/µL), NLR* (preoperative, POD1*, and
POD7*)

*Note: 40 patients enrolled, 1 excluded due to psychiatric disorder, 3 excluded due to need for an additional surgical procedure
VAS: Visual Analog Scale; PCA: Patient-controlled analgesia; CRP: C-reactive protein, NLR: Neutrophil to lymphocyte ratio;
POD1: Postoperative day 1; POD7: Postoperative day 7
(Kido et al., 2019)
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Appendix D
Data Collection Sheet #2
Appendix D.1
Joly, V., Richebe, P., Guignard, B., Fletcher, D., Maurette, P., Sessler, D. I., & Chauvin, M. (2005). Remifentanil-induced
postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology, 103(1), 147-155.
doi:10.1097/00000542200507000-00022/
Intraoperative Opioid & Ketamine
Doses

Group 1: Small-dose remifentanil (n=25): 0.05 mcg/kg/min remifentanil infusion plus a saline
placebo infusion
Group 2: Large-dose remifentanil (n=25): 0.4 mcg/kg/min remifentanil infusion plus a saline
placebo infusion
Group 3: Large-dose remifentanil + Ketamine (n=24): 0.4 mcg/kg/min remifentanil infusion with
0.5 mcg/kg bolus of ketamine and 5 mcg/kg/min infusion of ketamine until skin closure, then 2
mcg/kg/min x 48 hours postoperatively.

Postoperative Pain Score
VAS score at 24 hours
VAS score at 48 hours
Evidence of Hyperalgesia

Group 1 (n=25)
42 ± 26
43 ± 20

Group 2 (n=25)
44 ± 21
37 ± 23

Group 3 (n=24)
36 ± 20
33 ± 18

Tactile Pain Threshold: Von Frey Hair (g/mm2)
Group 1(n=25)
Group 2 (n=25)
Group 3 (n=24)
Preoperative
177 ± 0.5
178 ± 0.5
176 ± 1
24 Hours Postoperative
132 ± 7
106 ± 14┼
136 ± 8
┼
48 Hours Postoperative
138 ± 6
102 ± 14
140 ± 7
Extent of hyperalgesia (cm) to von Frey hair number 16 (pressure = 122 g/mm2)
Group 1 (n=25)
Group 2 (n=25)
Group 3 (n=24)
┼
24 Hours
7±6
12 ± 7
8.5 ± 6
Postoperative
48 Hours
5.5 ± 3
12 ± 7.5┼
6.5 ± 6.5
Postoperative
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Time to First Postoperative Opioid
Administration (min)
Postoperative Analgesic
Consumption

Morphine (mg)
PACU
Morphine (mg) 48
Hours
Postoperative

Group 1 (n=25)
35 (28-46)

Group 2 (n=25)
24 (20-33)

Group 3 (n=24)
41 (32-52)

Group 1 (n=25)
16 (10-24)

Group 2 (n=25)
20 (17-27)

Group 3 (n=24)
20 (14-23)

68 (50-91)

86 (59-109)‡

62 (48-87)

*Note: VAS: Visual Analog Scale; PCA: Patient-controlled analgesia; PACU: Post-anesthesia care unit
Data is shown as mean ± standard deviation or median (interquartile range).
┼
Indicates statistically significant results (p < 0.05) between group 1 & group 3
‡ Indicates statistically significant results (p < 0.01) in group 2 compared with group 1 & 3
(Joly et al., 2005)
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Appendix D.2
Yalcin, N., Uzun, S. T., Reisli, R., Borazan, H., & Otelcioglu, S. (2012). A comparison of ketamine and paracetamol for preventing
remifentanil induced hyperalgesia in patients undergoing total abdominal hysterectomy. International Journal of Medical
Sciences,9(5), 327-333. doi:10.7150/ijms.4222
Intraoperative Opioid & Ketamine
Doses

Postoperative Pain Score

Evidence of Hyperalgesia*

Group I (n=27): 0.4 mcg/kg/min remifentanil with saline infusion
Group II (n=26): 0.4 mcg/kg/min remifentanil infusion with ketamine infusion 5 mcg/kg/min and
0.5 mg/kg ketamine bolus
Group III (n=26): 0.4 mcg/kg/min remifentanil infusion with 1000 mg paracetamol infusion over
15 min pre-induction of anesthesia
*VAS 0
VAS 2
VAS 4
VAS 6
VAS 12
VAS 24

Baseline Inner Arm
Baseline Incision
24 hours Inner Arm
24 hours Incision
48 hours Inner Arm
48 hours Incision

Group I (n=27)
7.8
5.1
3.4
2.5
1.6
0.5

Group II (n=26)
6.7꙳
4.0꙳
2.4꙳
1.9꙳
0.8꙳
0꙳

Mean Pressure Pain Thresholds (Lb*)
Group I (n=27)
Group II (n=26)
4.2 ± 0.2
4.0 ± 1.3
3.8 ± 0.2
3.6 ± 1.1
4.2 ± 0.2
4.0 ± 1.3
┼
2.6 ± 0.1
4.9 ± 1.1꙳┼
4.0 ± 0.2
4.0 ± 1.3
2.6 ± 0.1┼
4.9 ± 1.1꙳ ┼

Group III (n=26)
7.2
4.2
2.4┼
1.7┼
0.8
0.2

Group III (n=26)
4.3 ± 1.0
4.0 ± 1.0
4.3 ± 1.0
4.9 ± 1.1┼
4.3 ± 1.0
4.9 ± 1.1┼
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Analgesic Demand via PCA
(Number of times button was
pressed)

Postoperative Analgesic
Consumption
(Actual morphine (mg) infused via
PCA)

Hours
2
4
6
12
24
48

Group I (n=27)
32.85 ± 8.19꙳
53.03 ± 12.19꙳ ┼
70.81 ± 15.03꙳ ┼
102.44 ± 27.49꙳ ┼
134.5 ± 41.07꙳ ┼
146.19 ± 21.20꙳ ┼

Group II (n=26)
23.0 ± 7.08
32.84 ± 11.83
40.61 ± 15.56
52.19 ± 20.40
60.11 ± 23.74
73.20 ± 15.63

Group III (n=26)
28.69 ± 7.01
39.34 ± 9.02
49.11 ± 11.70
66.73 ± 16.14
92.69 ± 20.44
104.81 ± 14.57

Hours
2
4
6
12
24
48

Group I (n=27)
15.66 ± 2.63꙳
26.11 ± 4.57꙳ ┼
36.70 ± 7.16꙳ ┼
57.07 ± 15.49꙳ ┼
73.03 ± 22.41꙳ ┼
86.05 ± 29.46꙳ ┼

Group II (n=26)
12.15 ± 3.0
18.46 ± 6.54
23.53 ± 8.96
30.92 ± 12.19
35.34 ± 13.71
45.52 ± 15.08

Group III (n=26)
14.03 ± 3.56
21.8 ± 6.13
28.15 ± 8.36
39.34 ± 11.50
48.53 ± 12.40
57.11 ± 16.71

Note: *VAS 0, VAS 2, VAS 4, VAS 6, VAS 12, VAS 24: Visual Analog Scores 0, 2, 4, 6, 12, and 24 hours postoperatively;
Evidence of hyperalgesia “mean pressure pain thresholds (Lb) determined with digital pressure algometer on inner forearm and the surgical incision area at the
preoperative period and then postoperative 24th and 48th hour” (p. 331); (Lb): Level of blunt pressure
Data is shown as mean or mean ± standard deviation.
꙳ Indicates statistically significant results between Group I and Group II (p < 0.05); ┼ Indicates statistically significant results between Group I & Group III
(p < 0.05); ‡ Indicates statically significant results between Group II and Group III (p < 0.05)
(Yalcin et al., 2012)
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Appendix D.3
Choi, E., Lee, H., Park, H. S., Lee, G. Y., Kim, Y. J., & Baik, H. (2015). Effect of intraoperative infusion of ketamine on remifentanilinduced hyperalgesia. Korean Journal of Anesthesiology, 68(5), 476-480.
Intraoperative Opioid & Ketamine
Doses

Group RL (n=25): 0.05 mcg/kg/min remifentanil infusion
Group RH (n=25): 0.3 mcg/kg/min remifentanil infusion
Group KRH (n=25): 0.3 mcg/kg/min remifentanil infusion with
0.5 mcg/kg bolus of ketamine and 5 mcg/kg/min infusion of ketamine

Postoperative Pain Score
NRS 0
NRS 6
NRS 24
Evidence of Hyperalgesia
Preoperative
Postoperative
Difference
Time to First Postoperative Opioid
Administration (min)
Postoperative Analgesic
Consumption

Ketorlac (mg)
Fentanyl (mcg)

RL (n=25)
4.0 ± 1.2
2.2 ± 1.1
1.2 ± 0.5

RH (n=25)
4.5 ± 1.6
2.9 ± 1.3┼
2.0 ± 1.5┼

KRH (n=25)
4.2 ± 1.1
2.0 ± 0.8
1.0 ± 0.5

Touch-Test Sensory Evaluation
RL (n=25)
RH (n=25)
4.05 ± 0.16
4.01 ± 0.46
3.92 ± 0.43
3.30 ± 0.78┼
-0.37 ± 0.37
-0.72 ± 0.72┼

KRH (n=25)
4.02 ± 0.16
3.76 ± 0.64
-0.27 ± 0.67

RL (n=25)
52.1 ± 27.0

RH (n=25)
39.6 ± 18.4

KRH (n=25)
51.6 ± 26.7

RL (n=25)
9.6 ± 14.3
243.3 ± 77.9

RH (n=25)
25.2 ± 18.7┼
310 ± 53.9┼

KRH (n=25)
16.8 ± 21.4
225.1 ± 38.1

Note: *NRS0, NRS6, NRS24: Numerical Rating Scale scores 0, 6, and 24 hours postoperatively
Data is shown as mean ± standard deviation.
┼
Indicates statistically significant results (p < 0.05)
(Choi et al., 2015)

81

Appendix D.4
Leal, P. C., Salomão, R., Brunialti, M. K., & Sakata, R. K. (2015). Evaluation of the effect of
ketamine on remifentanil-induced hyperalgesia: A double-blind, randomized study. Journal of Clinical Anesthesia,27(4), 331337. doi:10.1016/j.jclinane.2015.02.002
Intraoperative Opioid & Ketamine
Doses

Group 1 (n=28): 0.4 mcg/kg/min remifentanil infusion with 5 mcg/kg/min ketamine infusion
Group 2 (n=28): 0.4 mcg/kg/min remifentanil infusion with saline infusion

Postoperative Pain Score
*NRS 1
NRS 6
NRS 18
NRS 24

Evidence of Hyperalgesia

Group 1 (n=28)
4.6 (3.0)
0.9 (1.2)
1.57 (1.8)
1.4 (1.5)

Group 2 (n=28)
5.1 (2.5)
0.7 (1.0)
1.3 (1.6)
0.8 (1.0)

Von Frey Monofilament
Thenar Eminence:
- Preoperative
- 24 hours postoperative
Periumbilical:
- Preoperative
- 24 hours postoperative

Group 1 (n=28)

Group 2 (n=28)

300 (0)
290 (54.8) ┼

300 (0)
247 (115) ┼

279 (77.1)
248 (114)

269 (92)
205 (140)

Algometer
Thenar Eminence:
- Preoperative
- 24 hours postoperative
Periumbilical:
- Preoperative
- 24 hours postoperative

Group 1 (n=28)

Group 2 (n=28)

2.51 (1.43)
0.56 (0.44)

2.19 (0.92)
0.51 (0.44)

3.6 (1.5)
3.5 (1.6)

3.9 (1.4)
3.7 (1.7)
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Evidence of Hyperalgesia

Time to First Postoperative Opioid
Administration (min)
Postoperative Analgesic
Consumption

Interleukin Levels (pg/mL)
*IL-6:
- Preoperative
- 5 hours after incision
- 24 hours postoperative
IL-8:
- Preoperative
- 5 hours after incision
- 24 hours postoperative
IL-10:
- Preoperative
- 5 hours after incision
- 24 hours postoperative

Group 1 (n=28)

Group 2 (n=28)

3.3 (9.5)
29.3 (23.6)
24.1 (21.3)

2.1 (3.4)
34.8 (48.7)
24.8 (31.5)

3.3 (4.1)
8.0 (6.8)
6.0 (7.2)

2.2 (3.2)
11.3 (15.1)
4.5 (6.1)

7.8 (20)
9.1 (19.1)
8.6 (18.5)

1.9 (3.3)
5.5 (7.9)
5.0 (5.5)

Group 1 (n=28)
18 (0-600)

Group 2 (n=28)
15 (2-130)

Morphine (mg)
Group 1 (n=28)
Group 2 (n=28)
27.4 (18.3)
27.7 (12.9)

Note: *NRS1, NRS6, NRS 18, NRS24: Numerical Rating Scale scores 1, 6, 18, and 24 hours postoperatively; IL: Interleukin
Data is shown as mean (standard deviation) or (minimum value – maximal value)
┼
Indicates statistically significant results (p < 0.05)
(Leal et al., 2015)
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Appendix D.5
Kido, K., Toda, S., Shindo, Y., Miyashita, H., Sugino, S., & Masaki, E. (2019). Effects of low-dose ketamine infusion on remifentanilinduced acute opioid tolerance and the inflammatory response in patients undergoing orthognathic surgery. Journal of Pain
Research,12, 377-385. doi:10.2147/jpr.s177098
Intraoperative Opioid &
Ketamine Doses

Postoperative Pain Score

Evidence of Hyperalgesia

Group RH (n=12): 0.6 mcg/kg/min remifentanil infusion
Group RL (n=12): 0.2 mcg/kg/min remifentanil infusion
Group KRH (n=12): 0.6 mcg/kg/min remifentanil infusion with 0.5 mcg/kg bolus of ketamine and 5
mcg/kg/min infusion of ketamine
VAS score at 1 hour
VAS score at 3 hours
VAS score at 6 hours
VAS score at 12 hours
VAS score at 24 hours

Inflammatory Markers
*CRP (mg/dL):
- Preoperative
- POD 1
- POD 7
Neutrophils (x1000µL):
- Preoperative
- POD 1
- POD 7
Lymphocytes (x1000µL):
- Preoperative
- POD 1
- POD 7

Group RH (n=12)
35 ± 14
34 ± 14
21 ± 15
23 ± 19
18 ± 14

Group RL (n=12)
22 ± 15
20 ± 15
18 ± 14
22 ± 15
19 ± 11

Group KRH (n=12)
31 ± 24
22 ± 15
20 ± 15
15 ± 11
12 ± 7

Group RH (n=12)

Group RL (n=12)

Group KRH (n=12)

0.0
4.1 ± 1.8
0.5 ± 0.6

0.0
3.4 ± 1.8
04 ± 0.8

0.0
3.9 ± 1.3
0.6 ± 0.9

3.4 ± 0.9
15.6 ± 2.4
6.0 ± 2.2

3.2 ± 1.4
14.9 ± 3.0
4.5 ± 2.1

3.0 ± 0.8
14.9 ± 3.3
4.5 ± 2.1

2.0 ± 0.4
1.2 ± 0.3
1.9 ± 0.5

2.1 ± 0.6
1.0 ± 0.3
2.1 ± 0.5

1.8 ± 0.3
0.8 ± 0.3꙳
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1.8 ± 1.3
Inflammatory Markers

Group RH (n=12)

Group RL (n=12)
Group KRH (n=12)

Evidence of Hyperalgesia

*NLR:
- Preoperative
- POD 1
- POD 7

Analgesic Demand via PCA
(Number of times button was
pressed in 24 hours
postoperatively)
Postoperative Analgesic
Consumption

1.8 ± 0.5
14.0 ± 3.8
3.7 ± 2.6

Group RH (n=12)
12.8 ± 9.3 ɸΞ

24 hour
Postoperative
fentanyl dose
(mcg/kg)

1.6 ± 0.7
15.8 ± 4.4
2.2 ± 0.9

Group RL (n=12)
5.9 ± 2.3

1.7 ± 0.6
19.0 ± 6.6┼‡
2.6 ± 1.3

Group KRH (n=12)
4.8 ± 5.0

Group RH (n=12)

Group RL (n=12)

Group KRH (n=12)

4.65 ± 3.34 ɸΞ

2.41 ± 1.06

1.65 ± 1.62

*Note: VAS: Visual Analog Scale; PCA: Patient-controlled analgesia
Data is shown as mean ± standard deviation
꙳ Indicates statistically significant results between Group KRH and Group RH (p < 0.05)
┼
Indicates statistically significant results between Group KRH and Group RL (p < 0.05)
‡ Indicates statically significant results between Group KRH and Group RH (p < 0.001)
ɸ Indicates statistically significant results between Group RH and Group RL (p< 0.05)
Ξ Indicates statistically significant results between Group RH and Group KRH (p < 0.01)
(Kido et al., 2019)
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Appendix E
Critical Appraisal Skills Programme (CASP) Checklist: Randomized Control Trials
Appendix E.1: CASP Checklist
Joly, V., Richebe, P., Guignard, B., Fletcher, D., Maurette, P., Sessler, D. I., & Chauvin, M. (2005). Remifentanil-induced
postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology, 103(1), 147-155.
doi:10.1097/00000542-200507000-00022
A. Are the results of the RCT valid?

1. Did the trial address a clearly focused issue?

YES
X

2. Was the assignment of patients to treatments randomized?

X

3. Were all of the patients who entered the trial properly accounted for at its conclusion?

X

4. Were patients, healthcare workers, and personnel ‘blind’ to treatment?

X

5. Were groups similar at the start of the trial?

X

CAN’T TELL

6. Aside from the experimental intervention, were the groups treated equally?

NO

X

B. What are the results?
7. How large was the treatment effect?

75 patients undergoing major abdominal surgery

8. How precise was the estimate of the treatment effect?

Ketamine was shown to reduce the incidence of OIH*

C. Will the results help locally?
9. Can the results be applied in your context?
10. Were all clinically important outcomes considered?
11. Are the benefits worth the harm and cost?
*Note: OIH: Opioid-induced hyperalgesia
Patients in the small dose remifentanil group were anesthetized with larger doses of Desflurane

YES
X
X
X

CAN’T TELL

NO
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Appendix E.2: CASP Checklist
Yalcin, N., Uzun, S. T., Reisli, R., Borazan, H., & Otelcioglu, S. (2012). A comparison of ketamine and paracetamol for preventing
remifentanil induced hyperalgesia in patients undergoing total abdominal hysterectomy. International Journal of Medical
Sciences,9(5), 327-333. doi:10.7150/ijms.4222
A. Are the results of the RCT valid?

YES

1. Did the trial address a clearly focused issue?

X

2. Was the assignment of patients to treatments randomized?

X

3. Were all of the patients who entered the trial properly accounted for at its conclusion?

X

4. Were patients, healthcare workers, and personnel ‘blind’ to treatment?

X

5. Were groups similar at the start of the trial?

X

6. Aside from the experimental intervention, were the groups treated equally?

X

B. What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the treatment effect?
C. Will the results help locally?

NO

90 patients undergoing total abdominal
hysterectomy
Ketamine and paracetamol were both equally
effective in preventing OIH*
YES
CAN’T TELL
NO

9. Can the results be applied in your context?

X

10. Were all clinically important outcomes considered?

X

11. Are the benefits worth the harm and cost?

X

Note: OIH: Opioid-induced hyperalgesia

CAN’T TELL
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Appendix E.3: CASP Checklist
Choi, E., Lee, H., Park, H. S., Lee, G. Y., Kim, Y. J., & Baik, H. (2015). Effect of intraoperative infusion of ketamine on remifentanilinduced hyperalgesia. Korean Journal of Anesthesiology, 68(5), 476-480.
A. Are the results of the RCT valid?

YES

1. Did the trial address a clearly focused issue?

X

2. Was the assignment of patients to treatments randomized?

X

3. Were all of the patients who entered the trial properly accounted for at its conclusion?

X

4. Were patients, healthcare workers, and personnel ‘blind’ to treatment?
5. Were groups similar at the start of the trial?

CAN’T TELL

NO

X
X

6. Aside from the experimental intervention, were the groups treated equally?

X

B. What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the treatment effect?
C. Will the results help locally?

75 patients undergoing laparoscopic
gynecologic surgery
Ketamine was shown to attenuate OIH*
YES

9. Can the results be applied in your context?

X

10. Were all clinically important outcomes considered?

X

11. Are the benefits worth the harm and cost?

X

Note: OIH: Opioid-induced hyperalgesia
Patients in the low dose remifentanil group were anesthetized with larger doses of Desflurane

CAN’T TELL

NO
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Appendix E.4: CASP Checklist
Leal, P. C., Salomão, R., Brunialti, M. K., & Sakata, R. K. (2015). Evaluation of the effect of
ketamine on remifentanil-induced hyperalgesia: A double-blind, randomized study. Journal of Clinical Anesthesia,27(4), 331337. doi:10.1016/j.jclinane.2015.02.002
A. Are the results of the RCT valid?

YES

1. Did the trial address a clearly focused issue?

X

2. Was the assignment of patients to treatments randomized?

X

3. Were all of the patients who entered the trial properly accounted for at its conclusion?

X

4. Were patients, healthcare workers, and personnel ‘blind’ to treatment?

X

5. Were groups similar at the start of the trial?

X

6. Aside from the experimental intervention, were the groups treated equally?

X

B. What are the results?
7. How large was the treatment effect?
8. How precise was the estimate of the treatment effect?
C. Will the results help locally?
9. Can the results be applied in your context?

Note: OIH: Opioid-induced hyperalgesia

NO

56 patients undergoing a laparoscopic
cholecystectomy
Ketamine was not determined to prevent or
reduce OIH* when providing remifentanil
based anesthesia
YES
CAN’T TELL
NO
X

10. Were all clinically important outcomes considered?
11. Are the benefits worth the harm and cost?

CAN’T TELL

X
X
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Appendix E.5: CASP Checklist
Kido, K., Toda, S., Shindo, Y., Miyashita, H., Sugino, S., & Masaki, E. (2019). Effects of low-dose ketamine infusion on remifentanilinduced acute opioid tolerance and the inflammatory response in patients undergoing orthognathic surgery. Journal of Pain
Research,12, 377-385. doi:10.2147/jpr.s177098
A. Are the results of the RCT valid?

YES

1. Did the trial address a clearly focused issue?

X

2. Was the assignment of patients to treatments randomized?

X

3. Were all of the patients who entered the trial properly accounted for at its conclusion?

X

4. Were patients, healthcare workers, and personnel ‘blind’ to treatment?

X

5. Were groups similar at the start of the trial?

X

6. Aside from the experimental intervention, were the groups treated equally?
B. What are the results?

X

7. How large was the treatment effect?
8. How precise was the estimate of the treatment effect?
C. Will the results help locally?

CAN’T TELL

40 patients undergoing orthognathic
surgery
Ketamine was determined to prevent acute
opioid tolerance
YES
CAN’T TELL
NO

9. Can the results be applied in your context?

X

10. Were all clinically important outcomes considered?

X

11. Are the benefits worth the harm and cost?

NO

X
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Appendix F
Cross Study Analysis
Study
Joly et al.,
(2005)

Intraoperative Opioid & Ketamine
Doses
75 patients undergoing major
abdominal surgery were divided into 3
groups:
Group 1: Small-dose remifentanil
(n=25): 0.05 mcg/kg/min remifentanil
infusion plus a saline placebo infusion
Group 2: Large-dose remifentanil
(n=25): 0.4 mcg/kg/min remifentanil
infusion plus a saline placebo infusion
Group 3: Large-dose remifentanil +
Ketamine (n=24): 0.4 mcg/kg/min
remifentanil infusion with 0.5 mcg/kg
bolus of ketamine and 5 mcg/kg/min
infusion of ketamine until skin closure,
then 2 mcg/kg/min x 48 hours
postoperatively.

Evidence of Hyperalgesia
Extent of hyperalgesia was measured
using von Frey hair number 16
(pressure = 122 g/mm2) adjacent to the
surgical wound.
An algometer was used to establish a
pain pressure threshold (kPa).
Preoperative tactile pain thresholds
were similar among the 3 groups.
Measurements at 24 hours and 48 hours
postoperative were significantly
(p < 0.01) higher in group 2 compared
with groups 1 & 3.

Results
No significant differences in
postoperative pain scores at 24 hours
and 48 hours postoperatively.
No significant difference in time (min)
to first postoperative morphine dose or
amount of morphine (mg) administered.
Group 2 received a significantly (p <
0.01) higher total dose of morphine
(mg) compared with groups 1 & 3, 48
hours postoperatively

Large-dose intraoperative remifentanil
Extent of hyperalgesia to von Frey hair was shown to induce hyperalgesia. This
number 16 was significantly higher (p < phenomenon was prevented by
0.05) in group 2, compared to groups 1 administration of ketamine.
& 3.
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Study
Yalcin et
al., (2012)

Intraoperative Opioid &
Ketamine Doses
90 patients undergoing
total abdominal
hysterectomy divided into
3 groups:
Group I (n=27): 0.4
mcg/kg/min remifentanil
with saline infusion
Group II (n=26): 0.4
mcg/kg/min remifentanil
infusion with ketamine
infusion 5 mcg/kg/min
and 0.5 mg/kg ketamine
bolus
Group III (n=26): 0.4
mcg/kg/min remifentanil
infusion with 1000 mg
paracetamol infusion over
15 min pre-induction of
anesthesia

Evidence of Hyperalgesia
Hyperalgesia was quantified
using mean pressure pain
threshold (Lb) with a digital
pressure algometer on inner
forearm & at surgical incision
24 & 48 hours postop
Baseline values comparable
among three groups
Mean pressure pain thresholds
(Lb) at 24 & 48 hours postop
at surgical incision
significantly lower in group I
compared to groups II & III
Group I: lower pressure pain
thresholds at 24 & 48 hours
postop than their baseline
values, indicating
hyperalgesia.
Groups II & III: significantly
(p < 0.05) higher pressure pain
thresholds at 24 & 48 hours
postop compared with baseline
values, indicating attenuation
of the hyperalgesic response
with paracetamol and
ketamine.

Results
Postop VAS scores:
- Significantly higher (p < 0.05) in group I compared to group
II at 0, 2, 4, 6, 12, & 24 hours postop
- Significantly higher (p < 0.05) in groups I compared to group
III at 4 & 6 hours postop
- Not statistically significant between groups II & III
Analgesic demand via PCA pump:
- Significantly higher (p < 0.05) between group I compared to
group II at 2, 4, 6, 12, 24, & 48 hours postop
- Significantly higher (p < 0.05) in group I compared to group
III at 4, 6, 12, 24, & 48 hours postop
- Significantly (p < 0.05) higher in group III compared to group
II at 24 & 48 hours postop
Morphine consumption (mg) via PCA pump:
- Significantly (p < 0.05) higher in group I compared to group
II at 2, 4, 6, 12, 24, & 48 hours postop
- Significantly (p < 0.05) higher in group I compared to group
III at 4, 6, 12, 24, & 48 hours postop
- Significantly (p < 0.05) higher in group III compared to group
II at 24 & 48 hours postop
Paracetamol & ketamine were both shown to be equally
efficacious in preventing opioid-induced hyperalgesia
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Study
Choi et al.,
(2015)

Intraoperative Opioid &
Ketamine Doses
75 patients undergoing
laparoscopic gynecologic
surgery divided into 3
groups:

Evidence of Hyperalgesia

Results

Hyperalgesia measured adjacent to the wound
preop & 24 hours postop to conduct Touch-Test
sensory evaluation. Difference between the two
values was measured; higher negative number
indicates a hyperalgesic response.

NRS pain scores significantly
(p < 0.05) higher in group RH compared
to groups RL & KRH at 6 & 24 hours
postop

Group RL (n=25): 0.05
mcg/kg/min remifentanil
infusion

Preop baseline values of Touch-Test sensory
evaluation was similar among 3 groups

No significant difference between time
(min) to first postop opioid
administration among the 3 groups

Group RH (n=25): 0.3
mcg/kg/min remifentanil
infusion

24 hour postop Touch-Test sensory evaluation
values significantly lower in group RH
compared to groups RL & KRH.

Postop ketorolac (mg) consumption
significantly (p < 0.05) higher in group
RH compared to groups RL & KRH

Group KRH (n=25): 0.3
mcg/kg/min remifentanil
infusion with 0.5 mcg/kg
bolus of ketamine and 5
mcg/kg/min infusion of
ketamine

Difference was more negative in group RH
compared to groups RL & KRH indicating
hyperalgesic response in group RH.

Postop fentanyl (mcg) consumption
significantly higher (p < 0.05) in group
RH compared to groups RL & KRH
Opioid-induced hyperalgesia was shown
to be reduced by ketamine administration
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Study
Leal et al.,
(2015)

Intraoperative Opioid &
Ketamine Doses
56 patients undergoing
laparoscopic
cholecystectomy:
Group 1 (n=28): 0.4
mcg/kg/min remifentanil
infusion with 5 mcg/kg/min
ketamine infusion

Evidence of Hyperalgesia

Results

Hyperalgesia measured using Von Frey
monofilaments & an algometer at the
thenar eminence & periumbilical region
preop & 24 hours postop to measure pain
threshold.

Pain scores at 1 hour postop were significantly
(p < 0.05) lower in group 1 compared to group 2

Blood samples taken preop, 5 hours after
incision, & 24 hours postop to measure
IL-6, IL-8, & IL-10 levels which were
Group 2 (n=28): 0.4
hypothesized to be a component of the
mcg/kg/min remifentanil
inflammatory response associated with
infusion with saline infusion hyperalgesia.
Significant (p < 0.05) difference in the
hyperalgesic response at the thenar
eminence in group 1 compared to group 2
No other significant hyperalgesic
responses between groups 1 & 2 at the
thenar eminence or periumbilical region
No significant difference in IL-6, IL-8, or
IL-10 levels preop, 5 hours after incision,
or 24 hours postop in group 1 & 2.

No significant difference in time to first
postoperative opioid administration (min)
between group 1 and group 2
No significant difference in total, 24 hour,
postop morphine consumption (mg) between
group 1 and group 2
Ketamine was not shown to attenuate the
response to opioid-induced hyperalgesia
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Study
Kido et al.,
(2019)

Intraoperative Opioid &
Ketamine Doses
40 patients undergoing
orthognathic surgery
divided into 3 groups:
Group RH (n=12): 0.6
mcg/kg/min remifentanil
infusion
Group RL (n=12): 0.2
mcg/kg/min remifentanil
infusion
Group KRH (n=12): 0.6
mcg/kg/min remifentanil
infusion with 0.5 mcg/kg
bolus of ketamine and 5
mcg/kg/min infusion of
ketamine

Evidence of Hyperalgesia
Inflammatory markers: CRP, neutrophils,
lymphocytes, and NLR measured preop to
obtain baseline & measured POD 1 & POD 7
No significant differences in CRP levels among
any groups preop, POD 1, or POD 7
No significant differences in neutrophil levels
among any groups preop, POD 1, or POD 7.
POD 1:
- Lymphocyte levels significantly
(p < 0.05) lower in group KRH compared
to group RH
- NLR levels significantly higher
(p < 0.001) in group KRH compared to
group RH
- NLR levels significantly higher
(p < 0.05) in group KRH compared to
group RL

Results
No significant differences in postop VAS
scores between groups RH, RL, or KRH.
Analgesic demand via PCA pump:
- Group RH had significantly (p < 0.05)
higher analgesic demand compared to
group RL.
- Group RH had significantly (p < 0.01)
higher analgesic demand compared to
group KRH
24 hour postop fentanyl (mcg/kg) requirement:
- Group RH had significantly (p < 0.05)
higher requirement compared to group RL
- Group RH had a significantly (p < 0.01)
higher requirement compared to group
KRH.
High dose remifentanil (group RH) was
associated with higher postop analgesic
demand, opioid requirements & hyperalgesia
Administration of ketamine with remifentanil
anesthesia decreased opioid-induced
hyperalgesia & postop opioid requirements
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